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I. Abstract 
 
Brain metastasis is associated with a high risk for venous thromboembolism (VTE), 
which determines the prognosis of the patient. We postulated that von Willebrand 
factor (VWF), a procoagulant glycoprotein stored in endothelial cells (ECs) and 
platelets, contributes to VTE and promotes metastasis in the brain. Previously, it was 
shown that EC activation and the subsequent formation of luminal VWF fibers 
mediate the recruitment of platelets promoting tumor-associated vessel occlusion and 
pulmonary metastasis. However, little is known about the function of VWF within the 
specialized vascular bed of the blood-brain barrier. The aim of this project is to 
determine the contribution of VWF in the pathophysiology of brain metastasis. 
Using in vitro approaches significant lower levels of VWF were detected in primary 
human microvascular brain ECs compared to macrovascular human umbilical vein 
ECs. This was reflected by a restricted release of VWF and low numbers of luminal 
VWF fibers upon tumor cell-induced brain EC activation. In line, brain microvessels of 
wild type mice showed low amounts of stored VWF and few VWF-platelet 
aggregates. However, immunofluorescence analyses of brain tissue from patients 
with brain metastasis revealed a strong formation of luminal VWF-platelet aggregates 
mediating vessel occlusions. These findings were confirmed in the ret transgenic 
mouse model, which develops spontaneous melanoma with metastasis in the brain: 
metastatic ret mouse brains showed a strong formation of intravascular VWF-platelet 
aggregates. Importantly, this phenomenon was already observed in brains of ret 
transgenic mice without visible cerebral metastasis, suggesting that luminal VWF 
fibers are involved in initial steps of the brain metastatic cascade. High resolution 
microscopy techniques revealed the contribution of activated platelets in the 
formation of luminal VWF networks in the brain. Consistent with this, aggregometry 
assays and in vitro microfluidic model of brain microcirculation showed that the lack 
of VWF in platelets (VWF-/-) resulted in a reduced platelet aggregation. Additionally, 
impedance measurements and transmigration assays demonstrated that blocking 
platelet activation with the low molecular weight heparin Tinzaparin reduces the 
impact of platelet-mediated endothelium disruption and the transmigration of tumor 
cells. Furthermore, systemic anticoagulation using Tinzaparin reduced platelet 
accumulation and VWF networks in ret mouse brains. The impact of anticoagulation 
on brain metastasis formation was examined after intracardiac injection of melanoma 
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cells in mice treated with Tinzaparin. Quantification of brain metastasis showed that 
Tinzaparin attenuates the metastatic load compared to non-treated control mice. 
In summary, our findings provide new insights into the mechanisms by which platelet-
derived VWF promotes cerebral thrombosis and identifies platelet activation as a 
promising therapeutic target for the prevention of brain metastases. 
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II. Zusammenfassung 
 
Tumorpatienten mit Hirnmetastasen haben ein hohes Risiko venöse 
Thromboembolien (VTE) zu erleiden, was mit einer beschleunigten 
Tumorprogression und einer schlechten Prognose betroffener Patienten assoziiert 
ist. Aus dieser Erkenntnis resultiert die Hypothese, das Gerinnungsprotein von 
Willebrand Faktor (VWF), welches in Endothelzellen und zirkulierenden Blutplättchen 
gespeichert wird, nicht nur die Entstehung einer Thrombose vermittelt, sondern auch 
eine Metastasierung in das Gehirn fördert. In früheren Arbeiten konnte gezeigt 
werden, dass eine Tumorzelle das vaskuläre Endothel aktiviert. Die Konsequenz 
dieser Interaktion ist die Freisetzung von VWF, welcher unter Scherfluss fadenartige 
Netzerke ausbildet, Blutplättchen bindet und so thrombotische Gefäßverschlüsse und 
eine erfolgreiche Metastasierung in die Lunge unterstützt. Obwohl VWF folglich die 
Tumorprogression beeinflusst, bleibt dessen Funktion im spezialisierten Endothel der 
Blut-Hirn-Schranke unklar. Ziel der hier formulierten Arbeit war es daher, den Einfluss 
von VWF auf die Pathophysiologie von Hirnmetastasen zu untersuchen.  
Es konnte gezeigt werden, dass primäre humane mikrovaskuläre Endothelzellen des 
Gehirns in vitro deutlich weniger VWF exprimieren, als makrovaskuläre 
Endothelzellen der Nabelschnurvene. Folglich belegten Stimulationsexperimente und 
Immunfluoreszenzen eine limitierte VWF Freisetzung und luminale Fadenbildung des 
zerebralen Endothels nach Aktivierung durch Melanomzellüberstand. Dieser Befund 
konnte auch in vivo an Gewebeschnitten von Maushirnen verifiziert werden, wobei 
nur wenig VWF und einzelne Thrombozyten in zerebralen Blutgefäßen detektiert 
wurden. Im Gegensatz dazu wurde in Gewebeproben humaner Hirnmetastasen und 
im ret transgenen Mausmodell, welches spontan maligne Melanome und Metastasen 
im Gehirn entwickelt, eine starke Zunahme luminaler VWF-Plättchen Aggregate 
beobachtet. Interessanterweise zeigte die gleiche Analyse VWF Fäden und 
Mikrothrombosierungen im zerebralen Gefäßsystem bevor Metastasen detektiert 
werden konnten. Das ist ein relevanter Befund, der eine plausible Erklärung für frühe 
Schritte in der Metastasierung liefert. Weiterhin konnten durch Implementierung 
hochauflösender Fluoreszenzmikroskopie, aktivierte Thrombozyten identifiziert 
werden, welche VWF Netzwerke freisetzen. Durch Aggregometrie und 
mikrofluidische Systeme zur Simulation der zerebralen Mikrozirkulation konnte 
gezeigt werden, dass VWF-defiziente Blutplättchen transgener Mäuse ein reduziertes 
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Aggregationsverhalten aufweisen. In diesem Zusammenhang wurde der Einfluss von 
Antikoagulatien auf die Thrombozyten mit Impedanzmessungen und 
Transmigrationsversuchen untersucht. Hierbei zeigte sich, dass das 
niedermolekulare Heparin Tinzaparin durch Blutplättchen induzierte lokale 
Änderungen der der endothelialen Barriere und eine Tumorzelltransmigration hemmt. 
In Übereinstimmung führte die Behandlung von tumortragenden ret transgenen 
Mäusen mit Tinzaparin zu einer signifikanten Verminderung von Plättchenaktivierung, 
VWF-Fadenbildung und Mikrothrombosierung im Gehirn. Letztlich konnte eine 
Therapie mit Tinzaparin nach intrakardialer Injektion von Melanomzellen, welche 
durch eine Bildung zerebralen Metastasen charakterisiert sind, deutlich die 
Metastasierung ins Gehirn reduzieren. 
Zusammenfassend liefern die Befunde neue mechanistische Einblicke, inwieweit 
thrombozytärer VWF tumorassoziierte Thrombophilie und die Metastasierung in das 
Gehirn fördert. Eine gezielte Hemmung der Plättchenaktivierung liefert somit 
vielversprechende Therapieoptionen zur Behandlung von Krebspatienten. 
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ECM Extracellular matrix 
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F Coagulation factor 
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HBMEC Human brain microvascular endothelial cells 
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IL-8 Interleukin-8 
LMWH Low molecular weight heparin 
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PBS-T Phosphate-buffered saline -Tween 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PS Phosphatidylserine 
PTX Pertussis toxin 
qPCR Quantitative polymerase chain reaction 
qRT-PCR 
Quantitative real-time polymerase chain 
reactions 
rcf Relative centrifugal force 
ret  Ret transgenic mouse 
Ret Sn Ret supernatant 
rh Recombinant human 
RNA Ribonucleic acid 
RT Room temperature 
TEER Transendothelial electrical resistance 
TF Tissue factor 
TFPI Tissue factor pathway inhibitor 
UFH Unfractionateded heparin 
ULVWF Ultra-large VWF fibers 
UVR Ultraviolet radiation 
UVA Ultraviolet A  
UVB Ultraviolet B 
UVC Ultraviolet C 
VEGF-A Vascular endothelial growth factor  
VEGF-A165 
Recombinant human Vascular endothelial 
growth factor A165 
VEGF-C Vascular endothelial growth factor C 
VEGFR-1 VEGF receptor-1 
VEGFR-2 VEGF receptor-2 
VTE Venous thromboembolism 
VWF Von Willebrand factor 
VWF-/- Von Willebrand factor deficient 
WPB Weibel-Palade body 
Wt Wild type 
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1. Introduction 
1.1 Malignant melanoma 
Malignant melanoma is a malignant neoplasm originating from the uncontrolled 
proliferation of degenerated melanocytes. Melanoma principally manifests on the 
skin (cutaneous melanoma) although it can also arise in mucosal surfaces, the 
uveal tract, and the leptomeninges (Matthews et al. 2017). The incidence of 
melanoma has substantially increased in the last decades (Figure 1) and the 
tendency suggests an increasing incidence in the next years (Guy et al. 2015). The 
American Cancer Society’s estimated that about 96,480 new patients will be 
diagnosed with melanoma in 2019, being the fifth most common cancer in the 
United States (ACS). Similarly, in Europe, around 100,000 new cases are reported 
every year (Antoni et al. 2016).  
 
Figure 1. The incidence of malignant melanoma. The incidence for the occurrence of 
malignant melanoma per 100,000 inhabitants in the United States of America. Data were 
obtained from the American Cancer Society (ACS). 
 
Although malignant melanoma accounts only for less than 5% of all skin 
malignancies, it is responsible for 80% of all the deaths from cutaneous cancer (Arlo 
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J. Miller and Martin C. Mihm 2008). When melanoma is diagnosed at an early 
stage, the lesion can be surgically resected and the prognosis is favorable with a 5-
year survival rate of 98% (ACS). In contrast, in advanced stages, malignant 
melanoma shows an aggressive behavior with rapid systemic dissemination and 
very bad prognosis (Tas 2012). Therefore, a good understanding of the melanoma 
biology is required for the development of successful therapies improving the 
outcome of the patients. 
 
1.1.1 Onset of malignant melanoma 
 
Many environmental factors and a genetic predisposition influence the development 
of malignant melanoma. For instance, excessive exposure to ultraviolet radiation 
(UVR) can induce genetic lesions, which lead to the malignant transformation of 
melanocytes (Narayanan, Saladi, and Fox 2010). The UVR is divided into three 
classes: ultraviolet A (UVA [315–400 nm]), ultraviolet B (UVB [280– 315 nm]) and 
ultraviolet C (UVC [100–280 nm]) radiation (Tran, Schulman, and Fisher 2008). The 
UVB radiation is mainly responsible for the development of skin cancer (Glanz, 
Buller, and Saraiya 2007). The damaging effects of UVB radiation on the skin entail 
a direct damage of the DNA (formation of cyclobutane pyrimidine dimers), gene 
mutations, inhibition of the tumor immune surveillance, oxidative stress and 
inflammatory responses (Meeran, Punathil, and Katiyar 2008). Altogether favor the 
formation of a nevus, which has the potential to acquire a malignant phenotype and 
metastasize (Bald et al. 2014). 
Regarding the genetic influence on the formation of cutaneous melanoma, 
Caucasian populations with light skin are predisposed to malignant melanoma due 
to a reduced production of melanin (Bradford 2009). Melanin is a photoprotective 
pigment produced by the skin melanocytes and distributed within the keratinocytes 
(Brenner and Hearing 2008). Melanin reduces the transmission of UVR through the 
epidermis, indeed, epidermis from Black people transmits significantly less UVR 
(7.4% of UVB and 17.5% of UVA) compared to Caucasian epidermis (24% of UVB 
and 55% UVA) (Gloster and Neal 2006). The reduced expression of melanin in 
Caucasian people is caused by a polymorphism in the melanocortin receptor 1 
(MC1R) resulting in a lower pigmentation (Switonski, Mankowska, and Salamon 
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2013). Additionally, during the last years a better understanding of the molecular 
biology of malignant melanoma has contributed to identify a series of oncogenes 
associated with the emergence and progression of melanoma malignancy (Table 
1). The occurrence of specific lesions in these oncogenes defines the etiology of 
the tumor (Kunz 2014). Nowadays, the identification and molecular-targeting of 
these oncogenes is implemented in the individual therapy of melanoma patients 
(Leonardi et al. 2018).  
Table 1. Oncogenes and intracellular signaling molecules involved in the 
development of malignant melanoma. 
Pathway Gene or Protein Function 
RAS and MAPK N-RAS Oncogene 
BRAF Oncogene 
 Mitogen-activated protein kinase-extracellular 
related kinase (MEK) 
Signal transduction 
Extracellular-related kinase 1 or 2 (ERK2 or 
ERK2) or mitogen activated protein kinase 
(MAPK) 
Signal transduction 
INK4A, CDK, and 
Rb 
Cyclin-dependent kinase inhibitor 2A or 
inhibitor kinase 4 A (CDKN2A or INK4A) 
Tumor suppressor gene 
 Cyclin-dependent kinase (CDK4) Cell growth promoter 
 Cyclin D1 (CCND1) Cell growth promoter 
 Retinoblastoma (Rb) Tumor suppressor gene 
ARF and p53 Alternate reading frame (ARF) Tumor suppressor gene 
 Tumor protein 53 (p53) Tumor suppressor gene 
 Mouse double minute 2 (MDM2) p53 ubiquitination 
 BCL-2 associated X protein (BAX) Induces cell death 
PTEN and AKT Phosphatase and tensin homologue (PTEN) Tumor suppressor gene 
 Phosphatidylinositol 3 kinase (PI3K) Cell signaling molecule  
 Protein kinase B (AKT or PKB) Cell survival promoter 
 BCL-2 antagonist of cell death (BAD) Induces cell death 
 Forkhead receptor (FKHR) Cell growth suppressor 
Note: Adapted from Miller and Mihm 2006. 
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According to the Clark model, the development of malignant melanoma can be 
divided into 5 steps (Clark et al. 1984) (Figure 2): a) The first step in melanoma 
development is the formation of a nevus. This is characterized by the proliferation of 
regular melanocytes due to defective activation of the proliferative pathways (mainly 
the mitogen-activated protein kinase [MAPK]/extracellular-related kinase [ERK] 
signaling pathways) (McCain 2013). b) The growth of the nevus is controlled by 
tumor suppressor genes, like the cyclin gene family (Flørenes et al. 2000). 
However, the accumulation of genetic lesions in these genes leads to a dysplastic 
phase characterized by uncontrolled proliferation of aberrant melanocytes. c) Next, 
the dysplastic nevus can enter into a new phase known as the radial growth, which 
is defined by the suppression of apoptotic mechanisms (i.e., by homozygous 
deletions in phosphatase and tensin homologue [PTEN]) (Agosto-Arroyo et al. 
2017). d) Then, the nevus evolves towards an invasive or vertical growth phase 
associated with the penetration through the basement membrane and the formation 
of an intradermal nodule (Betti et al. 2016). e) At this point, metastatic melanoma 
cells can dissociate from the primary nevus (i.e., Slug (Snai2) expression causes 
cell-cell desmosome dissociation) and migrate through the stroma until they 
eventually arrive at the circulatory system (Shirley et al. 2012). 
 
 
Figure 2. Tumor progression of malignant melanoma. Schematic overview showing 
different steps in the progression of malignant melanoma according to the Clark model. 
Adapted from Miller and Mihm 2006. 
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1.1.2 Mesenchymal transition of malignant melanoma 
 
Invasion of distant organs by tumor cells implies a complex process which includes 
the access of tumor cells to the circulatory system, the dissemination through the 
lymphatic system or the bloodstream, arresting on a vessel wall and extravasation 
into a new tissue, and finally the metastatic colonization of the new tissue (Lambert, 
Pattabiraman, and Weinberg 2017). 
To succeed, a tumor cell must develop a series of “abilities” which involve the 
remodeling of cell-cell interactions, the modification of cell polarity and the 
acquisition of motility skills, all generated by the activation of a new transcriptional 
program (Dongre and Weinberg 2019). This process is known as the epithelial-
mesenchymal transition (EMT) (Figure 3). 
In malignant melanoma, EMT is characterized by the downregulation of E-cadherin, 
an adhesion integrin important for the maintenance of cell-cell adhesion (Yan et al. 
2016). In turn, the expression of N-cadherin is enhanced promoting the motility of 
melanoma cells (Mrozik et al. 2018). Additionally, the overexpression of matrix 
metalloproteinases (MMPs), such as MMP2 or MMP3, promotes the degradation of 
the basement membrane and facilitating tumor cell access to ECs (Liu et al. 2017). 
The expression of αVβ3 integrin in melanoma cells facilitates the interaction with 
ECs and favors the transmigration towards the circulatory system (Pearlman et al. 
2017). 
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Figure 3. The Epithelial-mesenchymal transition. The initiation of the epithelial-
mesenchymal transition (EMT) is promoted by the expression of EMT-inducing transcription 
factors which enhance the disassembly of the epithelial cells and induce changes in their 
morphology, their motility and their invasive capacities. Adapted from Dongre and Weinberg 
2019. 
 
1.1.3 Malignant melanoma dissemination 
 
The dissemination of metastatic cells is the major cause of cancer mortality (Guan 
2015). Commonly, malignant melanoma starts its spreading through the lymphatic 
system (Tejera-Vaquerizo et al. 2012). The secretion of vascular endothelial grow 
factor C (VEGF-C) by malignant melanoma cells induces the growth of lymphatic 
vessels towards the primary tumor (Fankhauser et al. 2017). In turn, the infiltration 
of lymph vessels around the tumor tissue generates a proinflammatory 
microenvironment that promotes tumor progression (Karlsson et al. 2017). Indeed, 
tumor-induced expression of the chemokine ligand 1 (CCL-1) in the lymph nodes 
fosters the migration of malignant melanoma cells towards the lymphatic system 
(Das et al. 2013). Additionally, it has been described that lymphatic endothelial cells 
promote the expression of EMT-inducing transcription factors in tumor cells by 
activation of Notch 3 and β1-integrin signals in tumor cells (L. Liu et al. 2014; 
Pekkonen et al. 2018). Moreover, given the role of the lymphatic system in the 
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drainage of the extracellular fluids into the blood (Ji 2006), it has been suggested 
that lymphatic vessels may favor the communication between the tumor tissue and 
the blood stream facilitating the hematogenous dissemination to distant organs 
(Joyce and Pollard 2009). 
Tumor cell dissemination through the circulatory system is a complex process that 
can be divided in different steps. To intravasate into the blood stream, a tumor cell 
interact with the endothelium and transmigrate through the EC barrier (Reymond, 
D’Água, and Ridley 2013). In the blood, the shear stress and the immune 
surveillance greatly reduce the chances of a tumor cell to survive (Rejniak 2016). 
Therefore, circulating tumor cells (CTCs) rapidly bind to platelets (Labelle et 
al.2012.), which protect cancer cells from immune recognition, shear stress and 
facilitate CTC attachment to the endothelium (Leblanc and Peyruchaud 2016a). 
Attached CTCs interact with the ECs to extravasate into the new tissue (Bendas 
and Borsig 2012). In the new location, the metastatic cell must evade the immune 
response, adapt to the new microenvironment and then, proliferate (Chaffer and 
Weinberg 2011) (Figure 4). 
 
 
Figure 4. The hematogenous dissemination of a metastatic cell. The hematogenous 
dissemination of a metastatic cell can be divided in four major phases: (I) the activation 
of a metastatic phenotype (EMT) in a tumor cell. (II) The intravasation and circulation of 
metastatic cell through blood stream. (III) The extravasation in a foreign tissue. (IV) The 
proliferation and invasion of the distant organ (Ganapathy, Moghe, and Roth 2015). 
 
Interestingly, malignant melanoma exhibits a high incidence of metastasis to the 
lung (10-40%), the liver (14-20%) and the central nervous system (2-20%) 
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(Belhocine et al. 2006) and when this occurs the survival of patients is considerably 
reduced, with a 5-year survival rate of only 5-19% (Sandru et al. 2014).  
 
1.1.4 Therapeutic options 
 
Considering the characteristics of the tumor, such as its stage, metastasis locations 
and the genetic features different treatments are implemented: at early stages, the 
primary treatment consists on the surgical resection of the primary tumor including 
safety margins according to the Breslow thickness (Melanoma Research Alliance), 
usually this procedure is combined with adjuvant therapies which improve the 
clinical responses (Kwak et al. 2019). For disseminated melanoma, chemotherapy 
was the most common treatment option for many years. However, the capacity of 
tumor cells to develop drug resistance reduced the efficacy of this kind of 
treatments (Soengas and Lowe 2003). Nowadays, chemotherapy has been 
substituted by other therapies, and may be used in a palliative treatment (Wilson 
and Schuchter 2016).  
In the early nineties, immunotherapy appeared as a promising treatment option for 
cancer patients in advanced stage. Immunotherapy aims to activate the immune 
system to seek and destroy tumor cells: immunotherapy fosters the anti-tumor 
activity of T-cells, B lymphocytes, natural killer cells and dendritic cells, and in 
addition, inhibits pro-tumorigenic cells like regulatory T-cells and myeloid derived 
suppressor cells (Oiseth and Aziz 2017). The introduction of immune-checkpoint 
inhibitors, such as the anti-Programmed cell death protein 1 (PD-1) antibodies 
nivolumab or pembrolizumab or the anti-Cytotoxic T-lymphocyte-associated protein 
4 (CTLA-4) ipilimumab have revolutionized the treatment of melanoma patients 
during the last years. Indeed, it has been recently shown that the implementation of 
PD-1 inhibitors improves the response rates up to 44% with an 3-year overall 
survival of up to 52% (Hamid et al. 2013; Larkin et al. 2018). 
However, is known that the immunogenic tumor microenvironment can influence the 
immune system response and affects the efficacy of immunotherapies (Gasser, 
Lim, and Cheung 2017). In the last decade, the discovering of a series of mutations 
in genes involved in the proliferation and aggressiveness of melanoma cells 
(section 1.1.1) has promoted the development of promising molecular therapies, 
which target proteins derived from this mutated genes (Leonardi et al. 2018). For 
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example, in melanoma patients with BRAF mutation specific targeted therapies, 
with BRAF and MEK inhibitors combined with anti-PD-1 immunotherapies revealed 
a dramatic improvement of the prognosis of patients in advanced stage (Flaherty et 
al. 2012). 
Taken together, the last advances in cancer therapy have demonstrated promising 
results in the survival of cancer patients (Domingues et al. 2018). However, the 
prolonged survival of patients suffering malignancies has brought a new challenge 
for the oncologists, an increased incidence of brain metastasis (Franchino, Rudà, 
and Soffietti 2018).  
 
1.1.5 Melanoma brain metastasis 
 
Brain metastases are the most frequent intracranial tumors: compared to primary 
tumors in the brain the incidence of brain metastasis is 3 to 10-fold higher (Davis et 
al. 2012). The most common primary cancers in patients with brain metastasis are 
pulmonary malignancies (36–64%), breast cancer (15–25%) and skin (melanoma) 
(5–20%) (Stelzer 2017). 
It is important to note that the metastatic invasion of the brain differs from metastatic 
processes in other organs, mainly due to the special properties of the blood-brain 
barrier (BBB) constituted by the neurovascular unit. The principal element of the 
BBB is the cerebral blood vessel. Compared to other tissues, ECs from the BBB 
exhibit special characteristics. Intercellular boundaries are tightly sealed by the 
formation of tight junctions (TJs) and adherens junctions (AJs). Besides, cerebral 
ECs lack of fenestrae and exhibit a low transcytosis, which notably reduces both the 
paracellular and transcellular diffusion through the BBB (Obermeier, Daneman, and 
Ransohoff 2013). Additionally, astrocytes, pericytes and neurons form the 
neurovascular unit providing structural and functional support to the BBB (Wilhelm 
et al. 2013) (Figure 5). Therefore, the BBB presents a physical and functional 
barrier which maintains a strict regulation of the molecular and cellular trafficking 
between the peripheral blood and the CNS (W.-Y. Liu et al. 2012) This profound 
regulation of CNS homeostasis defends the neural tissue against, toxins, 
inflammatory processes and pathogen invasion (Daneman and Prat 2015). 
However, in malignant disease, this barrier function acts as a double-edged sword 
in the formation of cerebral metastasis (Fidler 2015). On the one hand, the BBB 
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limits the penetration of immune cells from the circulatory system into the brain 
parenchyma (Daneman and Prat 2015). On the other hand, a transient weakening 
of the BBB integrity allows the transmigration of tumor cells into the brain 
parenchyma (Blecharz et al. 2015), then, the BBB protects tumor cells from the 
immune response and drug delivery, limiting the therapeutic options for the patient 
(Wilhelm et al. 2013).  
 
 
Figure 5. The blood-brain barrier. Brain ECs are interconnected by a continuous line of 
tight junctions (TJs) and adherens junctions (AJ). Brain pericytes, astrocytes and nerve-
ending feet establish a close contact with brain ECs providing a structural and functional 
support to the blood-brain barrier. Adapted from Wilhelm et al. 2013. 
As it was mentioned before, malignant melanoma is the third most common tumor 
of brain metastasis (Davis et al. 2012). Indeed, 75% of melanoma patients in stage 
IV develop cerebral metastasis (Davies et al. 2011) and this is associated with a 
very poor prognosis with a median survival of only 4 to 5 months (Vosoughi et al. 
2018). The emergence of new treatments combining immune-checkpoint inhibitors 
with targeted therapies have significantly prolonged the survival of melanoma 
patients with brain metastasis (Harary, Reardon, and Iorgulescu 2019). However, 
despite the increased survival of these patients the development of a cerebral 
metastasis is still, with rare exceptions, a fatal complication (Fidler 2015). Therefore, 
to prevent the formation of brain metastasis is essential to understand the 
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mechanisms involved in the metastatic invasion of the CNS. Importantly, patients 
with brain metastases exhibit an enhanced systemic hypercoagulability, which 
accounts for a notable percentage of the mortality and morbidity reported due to the 
high risk of thromboembolic complications (Caine et al. 2002). 
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1.2 Cancer and thrombosis 
 
The association between cancer progression and thrombotic complications is well 
established since in 1865 the French physician Armand Trousseau described the 
correlation between gastric cancer and venous thromboembolism (VTE) (Trousseau 
1865). 
Indeed, it is estimated that 4-20% of the cancer patients suffer from VTEs at some 
stage of the disease (Abdol Razak et al. 2018). The highest incidences of VTE have 
been observed in patients with cancer of the brain, lung, uterus, pancreas, stomach, 
bladder and kidney (Sheth et al. 2017). The occurrence of VTEs is also related to 
the stage and aggressiveness of the disease. It has been shown that VTE incidence 
varies from 1% in some cancer entities and increases up to 20% in aggressive 
malignancies, such as pancreatic cancer and malignant gliomas (I. Pabinger and Ay 
2012). Consistent with this, patients with an advanced stage of malignant 
melanoma are at high risk of suffering VTEs (incidence of 25% in stage IV) (Sparsa, 
et al. 2011) and this risk is particularly increased in patients bearing cerebral 
metastases (Alvarado et al. 2012). The incidence of VTE is often associated with a 
poor prognosis, due to an elevated risk of metastasis and decreased survival (Wun 
and White 2009). Indeed, it was reported that cancer patients with VTEs exhibit a 
significant lower survival in the first year (12%) compared to patients without VTEs 
(36%) (Sørensen et al. 2000). Based on these observations, it can be speculated 
that CTC interact with the coagulation system and vascular ECs, promoting 
hypercoagulation and favoring metastasis.  
 
1.2.1 Melanoma and the activation of the plasmatic coagulation 
 
Cancer-associated activation of the coagulation depends on the ability of tumor 
cells to interact with the components of the plasmatic coagulation system. (Lima 
and Monteiro 2013). The major initiator of the coagulation cascade is the 
transmembrane protein Tissue factor (TF) (Mackman 2009). Under normal 
circumstances, physiological active TF is not in contact with the blood components. 
However, when vascular damage occurs subendothelial TF is exposed to the 
coagulation factors in the blood (Butenas et al. 2005). Additionally, inflammatory 
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conditions induce the expression of active TF in neutrophils and monocytes 
contributing to the activation of the coagulation(Bode and Mackman 2014; 
Darbousset et al. 2012). Exposed TF initiates the extrinsic coagulation cascade by 
the formation of the extrinsic tenase complex with activated factor (F) VII (FVIIa). 
The extrinsic tenase complex activates FIX and FX. Then, FXa together with 
activated FV (FVa) cleave FII (prothrombin) generating FIIa (thrombin) (Figure 6). 
In turn, the serine protease thrombin is an important regulator of 
platelet/thrombocyte aggregation and EC activation by cleaving the protease-
activated receptors (PARs) (Coughlin 2000).  
 
 
Figure 6. Plasmatic activation of thrombin. The coagulation factors  in the blood 
circulate as zymogens. Their eventual activation triggers their serine protease activity 
which cleaves the next zymogen in the coagulation cascade generating more serine 
proteases which finally activate fibrinogen (Chaudhry and Babiker 2019). Image adapted 
from Cugno and Tedeschi 2013. 
 
Interestingly, the expression of TF has been correlated with the aggressiveness of 
distinct tumor cell lines (Gerotziafas et al. 2012; Lima et al. 2011; Mueller et al. 
1992) In line with this, TF is frequently overexpressed on the surface of melanoma 
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cells (Kerk et al. 2010). Moreover, the activation of the tenase complex is enhanced 
by the expression of phosphatidylserine molecules in the extracellular matrix of 
melanoma cells, which provides an optimal negatively charged surface for the 
assembly of coagulation factors (Spronk, ten Cate, and van der Meijden 2014). 
Many clinical studies have shown the relation between TF expression in tumor cells 
and the progression of the disease. It was shown that elevated levels of plasmatic 
tumor-derived TF is associated with a high incidence of thromboembolic 
complication and increased metastases (Tesselaar et al. 2009; Yokota et al. 2009; 
Zwicker et al. 2009). Consistent with this, Tinholt and colleagues showed that 
enhanced expression of TF pathway inhibitor (TFPI) in breast tumors correlates 
with a better prognosis for the patients. In contrast, they also showed that patients 
with large tumors exhibit decreased expression of TFPI associated with elevated 
levels of plasmatic TF and multiple metastases (Tinholt et al. 2015). These findings 
suggest a strong link between the activation of the coagulation cascade and tumor 
dissemination. 
 
1.2.2 Interaction between tumor cells and the vascular endothelium 
 
An indispensable condition for metastasis dissemination is the interaction between 
tumor cells and the vascular endothelium. The crosstalk between tumor cells and 
ECs triggers a series of intracellular signaling pathways which modulate the 
phenotype of ECs (Pober 2002). This process is known as EC activation and turns 
the endothelium into a procoagulant and proadhesive surface which facilitates cell 
adhesion and extravasation (Blann 2012). 
Indeed, previous studies described how melanoma cells mediate EC activation. It 
was shown that the expression of TF on the surface of melanoma cells induces the 
generation of thrombin. This protease is not only involved in coagulation but also 
contributes to EC activation by cleaving the endothelial PAR-1 (Kerk et al. 2010). 
Additionally, melanoma cells secrete vascular endothelial growth factor A (VEGF-
A), which binds to the endothelial VEGF receptor 2 (VEGFR-2) and activates ECs 
(Desch et al. 2012). It was shown that this mechanism is further amplified by the 
secretion of MMP-2, which enhances the expression of VEGF-A via interaction with 
αVβ5 integrin and MMP-14 (Desch et al. 2012) (Figure 7). 
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One of the consequences of EC activation is the massive influx of calcium ions into 
the cytoplasm (Andrikopoulos et al. 2015; Cudmore et al. 2012). The increase of 
intracellular calcium activates Rab GTPases (Parkinson et al. 2014). Activated Rab 
GTPase triggers a complex signaling pathway, which ends up with the exocytosis of 
Weibel-Palade body (WPB) organelles (Nightingale and Cutler 2013). WPBs 
contain many different biomolecules, such as P-selectin, interleukin-8 (IL-
8),angiopoietin-2 (Ang-2) and von Willebrand factor (VWF), which are involved in 
angiogenesis, inflammation, coagulation and tissue repairing (Valentijn et al. 2011) 
(Figure 7). 
 
 
Figure 7. Mechanisms of endothelial cell activation. Indirect Activation: Melanoma cells 
activate the coagulation cascade by exposition of TF on their cell surface This interaction 
results in the generation of thrombin which cleaves PAR-1 on the surface of EC (Kerk et al. 
2010). Direct activation: Melanoma cells secrete VEGF-A which activates endothelial cells 
via VEGF receptor-2. VEGF-A secretion is enhanced in an autocrine fashion via MMP-2-
αvβ5 integrin interaction (Desch et al. 2012). Both pathways lead to the exocytosis of WPBs 
and luminal secretion of Ang-2, P-selectin and VWF. Adapted from Desch et al., 2012. 
 
 
 
↑[Ca2+] 
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1.2.3 Von Willebrand factor  
 
As it was described above, tumor-mediated EC activation triggers the exocytosis of 
WPBs. The most abundant constituent of WPBs is the prothrombotic glycoprotein 
VWF (Valentijn et al. 2011). This protein is principally stored by ECs in WPBs and 
by platelets in α-granules (Randi and Laffan 2017). 
The VWF precursor protein (pre-po VWF) is composed of 5 distinct domain groups: 
The propeptide domains D1 and D2, the D’D3 domains, the A domains (-A1-A2-A3-
), the D4 domain and the C domains (-C1-C2-C3-C4-C5-C6-CK) (Zhou et al. 2012). 
Each group of domains displays a specific binding site enabling VWF to bind 
several ligands simultaneously (Ruggeri 2003b) (Figure 8).  
 
  
Figure 8. Structure and binding sites of VWF.  The pre-pro VWF consists of a sequence 
of domains: (D1-2 group) - (D'D3 group) - (D4 group) -C1-C2-SS. In the Golgi apparatus 
the pro-pre VWF undergoes a maturation process by which the pro-peptide (D1 and D2 
group) is cleaved and VWF peptide is glycosylated. Each domain of the mature VWF 
glycoprotein shows a specific binding sites: Platelet glycoproteins GpIb and GpIIb/IIIa 
interact with the A1 and C1-C2 domains respectively; the coagulation factor VIII (FVIII) 
binds to the D3 domain; collagen binds to VWF in the A1-3 domains; and ADAMTS13 
cleaves VWF by the A2 domain Adapted from  www.shenc.de   
 
The synthesis of VWF is initiated in the rough endoplasmic reticulum where the pre-
pro VWF is dimerized by disulfide bridges in the C-terminal CK domains. Pre-pro 
VWF dimers are then delivered to the Golgi apparatus where the propeptide D1-2 is 
cleaved. Then, the VWF peptide is glycosylated resulting in a mature VWF 
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glycoprotein. The mature VWF plays a central role in primary blood hemostasis 
(Gale 2011): Under physiological conditions VWF is secreted into the abluminal 
surface of the vessel (J. W. Wang et al. 2011). When the vascular endothelium is 
disrupted, subendothelial VWF is exposed to the blood components and mediates 
the accumulation of thrombocytes at the site of the injury, preventing bleedings and 
contributing to vessel repair (Brass 2001; Eming, Krieg, and Davidson 2007) 
(Figure 9). 
 
 
Figure 9. Role of von Willebrand 
factor in vessel repair. ECs-
secreted prostacyclin and nitric 
oxide maintain platelets in a resting 
state. The enzyme CD39 expressed 
on the luminal surface of ECs 
hydrolyzes active ADP, impeding the 
activation of platelets by ADP. At 
sites of vascular injury, disruption of 
the endothelium exposes collagen 
fibrils and the subendothelial VWF. 
VWF exposition mediates the 
adhesion of platelets. Collagen 
activates platelets which secrete 
APD and thromboxane A into the 
lumen inducing the local formation of 
a platelets plug, which closes the 
gap in the vessel wall. Source: 
Brass 2001. 
 
 
 
In parallel, VWF is constitutively secreted into the plasma(Peyvandi, Garagiola, and 
Baronciani 2011a). In the plasma VWF binds to FVIII and protects it against 
proteolytic degradation, thereby, FVIII is available for the completion of the 
plasmatic coagulation cascade (Schrenk et al. 2010). Circulating VWF shows an 
inactive globular conformation which hides its binding domain A2 (Gragnano et al. 
2017). However, under certain conditions, such as high shear rates, globular VWF 
is rapidly elongated into a long string conformation becoming active (Crawley et al. 
2011) (Figure 10 A and B).  
In addition, mature VWF dimers are also polymerized and organized in helical VWF 
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tubules tightly packed in WPBs (Lenting, Christophe, and Denis 2015). Each WPB 
stores between 10,000 to 50,000 compacted tubular VWF multimers, which are 
responsible for the elongated shape of WPBs (Huck, Schneider, Gorzelanny, & 
Schneider, 2014). This “spring-loaded” structure of WPB-stored VWF facilitates the 
release of VWF towards the lumen when WPB exocytosis is promoted (Michaux et 
al. 2006). Under inflammatory conditions VWF is released from WPBs (KM et al. 
2010). The exposition of densely packed multimeric VWF tubules to the luminal 
conditions triggers a rapid elongation of VWF tubules and the formation of ultra-
large VWF (ULVWF) strings/fibers, a process favored by the hydrodynamic forces 
of the blood flow (Schneider et al., 2007). Still attached to the EC surface by 
interaction with P-selectin, integrin αVβ or membrane lipids ULVWF strings become 
activated by the exposure of their binding sites (Huck et al. 2014) (Figure 10 A-C).  
Activated VWF strings mediate the recruitment of platelets and leukocytes, 
contributing to tissue repair, coagulation and inflammation (Petri et al., 2010; 
Ruggeri, 2003). This process is strongly regulated by a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), 
which cleaves VWF in the A2 domain (Fujioka et al. 2010) and reduces the 
thrombogenic potential of an excessive formation of luminal ULVWF fibers (Lenting, 
Christophe, and Denis 2015) (Figure 9 D). 
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Figure 10. VWF activation and regulation. A. The globular VWF multimers are stored 
in WPBs of ECs. EC activation induces the release of VWF multimers into the vessel 
lumen. B. VWF multimers anchoraged to the endothelial surface are unfolded by the 
hydrodynamic forces of the bloodstream. C. Subsequently, the multimers crosslink and 
form intraluminal VWF threads on the endothelial surface. D. This process is regulated 
by the VWF-specific protease ADAMTS13 which cleaves VWF protein in the A2 domain. 
 
1.2.4 Pathology of dysregulated von Willebrand factor activity 
 
Due to the important contribution of VWF in the maintenance of blood hemostasis a 
deficient expression or dysregulated activation of VWF can lead to severe 
pathologies.  
The most frequent bleeding disorder caused by a deficient expression of VWF is the 
inherited von Willebrand disease (VWD). VWD is classified in three subtypes: The 
VWD type 1 is characterized by low levels of VWF (Sadler et al. 2003). The VWD 
type 2 presents more severe symptoms, it is caused by the occurrence of mutations 
in distinct domains affecting VWF functionality, multimerization or binding capacity 
(Tosetto and Castaman 2015). The VWD type 3 consists of a complete absence of 
VWF resulting in life-threatening hemorrhages (Phillips, Lazarchick, and Bergmann 
2016). Additionally, VWF deficiency can be acquired by the generation of 
autoantibodies against VWF which leads to the clearance of plasmatic VWF, this 
situation is defined as the acquired von Willebrand syndrome (AVWS) and is 
associated with severe bleedings (Federici 2006). 
Conversely, a defective regulation of intraluminal VWF activity is related to 
thrombotic complications. This situation is depicted in the Thrombotic 
thrombocytopenic purpura (TTP) disease, characterized by a deficient ADAMTS13 
activity (Mannucci and Peyvandi 2007). Two types of TTP have been described: the 
Moschcowitz syndrome associated with the generation of ADAMTS13 
autoantibodies which dampen the activity of this enzyme in the plasma, and the 
inherited ADAMTS13 deficiency or Upshaw-Schulman syndrome (Tsai 2007). Both 
disorders are characterized by the accumulation of luminal ULVWF fibers mediating 
platelet aggregation and subsequent vascular occlusion. Additionally, this condition 
leads to a pathological consumption of platelets and consequently to 
thrombocytopenia which results in critical bleeding episodes (Ferrari, Rottensteiner, 
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and Scheiflinger 2013). 
Furthermore, increased plasmatic levels of plasmatic VWF have been reported in 
several disorders associated with the occurrence of thrombotic events or 
microvascular damage. For instance, high levels of VWF were related to the 
incidence of thromboembolic strokes and myocardial infarctions (Conway et al. 
2003; Morange et al. 2004). Additionally, this phenomenon has been also detected 
in patients suffering nephritis, pregnancy-induced hypertension, diabetic angiopathy 
and pulmonary hypertension (Müller et al. 2002a). Interestingly, elevated levels of 
plasmatic VWF haven been also detected in patients with various types of 
malignancies (Damin et al. 2002; Röhsig et al. 2001; W.-S. Wang et al. 2005a). 
Consistent with this, significant deficiencies of ADAMTS13 activity have been also 
detected in patients with metastasis (Garam et al. 2018; Page et al. 1992; Rieger et 
al. 2005), suggesting the contribution of VWF in cancer-associated thrombotic 
complications. In line with this, a recent publication of our group showed the impact 
of intraluminal VWF on to the development of cancer-associated thrombotic vessel 
occlusion in a mouse model of malignant melanoma (Bauer, et al. 2015). In 
addition, in vitro studies have demonstrated that VWF supports the adhesion of 
tumor cells (Floyd et al. 1992; Gomes, Legrand, and Lafeve 2005). These data 
suggest a pivotal role of VWF promoting cancer-associated thrombotic 
complications on the one hand and metastasis on the other.  
 
1.2.5 Role of von Willebrand factor in cerebral pathologies 
 
Little is known about the impact of VWF on pathophysiological processes in the 
CNS. However, an increasing body of evidence shows that elevated levels of 
plasmatic VWF are associated with diverse neuropathologies, such as ischemic 
strokes or intracranial endothelial injury (Folsom et al. 1999; Sandsmark et al. 2019; 
H. Yokota 2007). In line with this, O’regan and colleagues reported that VWF-
mediated platelet and leukocyte recruitment in the brain compromises the integrity 
of the BBB and favors the progression of cerebral malaria (O’regan et al. 2016). 
Furthermore, it was shown that BBB stiffness is significantly enhanced in VWF-
deficient mice showing low permeability upon hypoxia or seizure insults (Suidan et 
al. 2013). Furthermore, the absence of VWF in mice has been correlated with a 
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reduced disruption of the BBB and smaller edemas formation after ischemic insults 
(Kleinschnitz et al. 2009; Zhu et al. 2016). These studies indicate a role of VWF in 
increasing the permeability of the BBB in cerebral pathologies. 
However, in an experimental model of pulmonary metastasis the absence of WPBs 
in VWF-deficient mice resulted in an increase of lung metastases (Terraube et al. 
2006) a process which is correlated with an increase of vascular permeability (M.J. 
et al. 2012). This suggests different roles of VWF regulating the permeability in 
different vascular beds. Indeed, the vasculature is an organ that exhibits a strong 
heterogeneity. and it was shown that distinct vascular beds show different features 
and properties according to its location and function (Cines et al. 1998). This affects 
the expression of many EC-derived proteins, including VWF (Yamamoto et al. 
1998). Given the specialized features of the CNS vasculature, characterized by a 
notable prothrombotic activity protecting the CNS from bleedings (Fisher 2013), the 
function and expression of VWF might be specifically regulated in the BBB to 
prevent pathological hypercoagulation.  
Here we asked whether the specific function of VWF in the brain vasculature may 
have an impact on the hypercoagulable state related to brain metastasis. 
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2 Aim of the project 
 
Hypercoagulability is a frequent complication in melanoma patients suffering from 
brain metastases. The aim of this project was to elucidate the relative contribution of 
endothelial cell-derived and platelet-derived von Willebrand factor in tumor-
associated thrombosis and brain metastasis. To this end, we have applied high 
resolution microscopy techniques, microfluidic assays, in vitro models of the blood-
brain-barrier and light transmission aggregometry assays. To confirm the clinical 
relevance of our findings, tissue samples from human metastatic brains were 
analyzed. Additionally, the ret transgenic mouse model of malignant melanoma with 
brain metastasis was implemented to study the contribution of VWF to brain 
metastasis in vivo. To examine the therapeutic impact of systemic anticoagulant on 
brain metastasis formation, the low molecular weight heparin Tinzaparin was 
evaluated in two different mouse models of brain metastasis. A better understanding 
of the mechanisms that contribute to the hypercoagulability associated with brain 
metastasis will lead to the discovering of potential targets for the development of 
novel therapeutic approaches. 
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3 Materials and methods 
 
3.1 Materials 
 
3.1.1 Laboratory equipment 
 
Device Product reference 
Balance CPA623S, Sartorius AG; Göttingen, 
Germany. 
Centrifuge I Heraeus® Megafuge 1.0R, DJB Labcare 
Ltd, Newport Pagnell, UK. 
Centrifuge II 5910 R, Eppendorf AG, Hamburg, 
Germany. 
Gel imaging system. Intas Gel IX Imager, INTAS Science 
Imaging Instruments GmbH. Göttingen, 
Germany. 
Electric Cell-substrate Impedance Sensing 
(ECIS) array 
ECIS® 8W10E+ PET array Applied 
BioPhysics, NY 12180, USA. 
Fluorescence Microscope Z1 AxioObserver inverted fluorescence 
microscope, Carl Zeiss AG; Oberkochen, 
Germany. 
ibidi Pump system: 
 ibidi Pump 
ibidi Perfusion Set 
ibidi Fluidic Unit 
ibidi GmbH, Martinsried, Germany. 
Cell culture incubators Heraeus® CO2 Incubator. BBD6220, 
Thermo Fisher Scientific, Waltham, USA. 
MCO-17AIC CO2 Incubator. SANYO 
Electric Biomedical Co., Ltd. Panasonic, 
Osaka, Japan. 
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Light transmission aggregometer CHRONO-LOG® Model 700, Chrono-log 
corporation, Harvertown, USA. 
LightCycler® LightCycler® 96 Sytem. Roche Life 
Sciences, Mannheim, Germany. 
Magnetic stirrer Mr 3001 Heidolph Instruments GmbH & CO. 
KG, Schwabach, Germany. 
Microplate Readers Power Wave XS2, BioTek Instruments, Inc; 
Winooski, VT, USA. 
Infinite® 200 PRO multiwell reader Life 
Sciences-Tecan Trading AG, Switzerland. 
Microtome Kryostat CM1900, Leica Microsystems; 
Wetzlar, Germany. 
NanoDrop NanoDrop™ 2000/2000c 
Spectrophotometer. Thermo Fisher 
Scientific, Waltham, USA. 
Reflected light Microscope Olympus CH2 Binocular Microscope, 
Olympus Europa SE & Co. KG, Hamburg, 
Germany. 
Stereo Microscope AF 90mm f/2.8, Tamron; Saitama, Japan. 
Thermal Cycler UNO Thermal Block, Biometra GmbH, 
Göttingen, Germany. 
Ultrapure water system PURELAB flex 3, ELGA LabWater,Hgh 
Wycombe, UK. 
Vortexers Vortex-Genie 2, Scientific Industries, Inc., 
NY, USA. 
Genius 3, IKA®-Werke GmbH & Co. KG; 
Staufen, Germany. 
Water bath TW20, Julabo GmbH; Seelbach, Germany. 
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3.1.2 Substances 
 
Name Product reference 
1,4-Diazabicyclo Octane (DABCO) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
4,6-Diamidino-2-Phenylindole (DAPI) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
CaCl2 Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
CellTrace™ Calcein Green, AM Invitrogen, Darmstadt, Germany. 
CellTrace™ Calcein Orange-red, AM Invitrogen, Darmstadt, Germany. 
D -Glucose (Dextrose) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Ethanol (ETOH) Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany. 
Bounding glue Fixogum, Marabu GmbH & Co. KG; 
Bietigheim-Bissingen, Germany 
Isoflurane Abbvie GmbH & Co. KG, Ludwigshafen am 
Rhein, Germany. 
KH2PO Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany. 
Methanol Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
MgCl2 Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Mowiol mounting medium Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Na2HPO4 Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
NaCl Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Polysorbat 20 Tween® 20, Carl Roth GmbH & Co. KG; 
Karlsruhe, Germany. 
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Triton X-100 Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Trypan blue Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Ultra-purified H2O  
2-Mercaptoethanol Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
 
3.1.3 Buffers and solutions 
 
Name Composition 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Blocking buffer I HEPES containing 0.3% TritonX-100 and 2% 
of BSA. 
Blocking Buffer II 10% Goat Serum in PBS-T. 
Citrated buffer S-Monovette, SARSTETD AG &Co., 
Nümbrecht, Germany. 
HEPES-buffered Ringer Solution (HBRS) 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 5 mM Glucose, 10 mM HEPES. 
Incubation Buffer HEPES containing 0.3% TritonX-100 
Phosphate Buffer Saline (PBS) 140 mM NaCl; 2.5 mM KCl; 6.5 mM Na2HPO4; 
1.5 mM KH2PO4. 
Phosphate Buffer Saline-Tween (PBS-T) 0.1% Tween® 20 in PBS. 
Platelet resuspension buffer (PRB) 5% BSA in PWB (pH = 7.4.) 
Platelet washing buffer (PWB) 
 
103 mM NaCl, 5 mM KCl, 3 mM NaH2PO4* 
H20, 5 mM HEPES, 5.5 mM Glucose ( pH = 
6.5) 
Saline Solution 0.9% NaCl. B Braun AG, Melsungen, 
Germany. 
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3.1.4 Reagents and Kits 
 
Reagents Product reference 
Adenosine 5'-diphosphate (ADP) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Alexa 488-conjugated fibrinogen Thermo Fisher Scientific, Waltham, USA. 
Angiopoietin-2-ELISA-Kit 
 
DuoSet® ELISA Development Systems, R&D 
Systems, Inc., Minneapolis, MN, USA. 
Apyrase Sigma-Aldrich, Inc.; St. Louis, USA. 
Bevacizumab Avastin, Roche Diagnos-tics GmbH, 
Mannheim, Germany. 
Bovine serum albumin (BSA) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Collagenase Sigma-Aldrich, Inc.; St. Louis, USA. 
Color Reagent A and Color Reagent B R&D Systems, Wiesbaden, Germany. 
Corning® Collagen type I Corning Life Sciences, Amsterdam, The 
Nederland. 
Fondaparinux Arixtra®, Sanofi; Paris, France. 
Goat serum Dako Denmark A/S; Glostrup, Denmark. 
Histamine Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Human Fibrinogen-Alexa Fluor™ 488 Thermo Fisher Scientific, Waltham, USA. 
Protease inhibitor E-64 Calbiochem, Darmstadt, Germany. 
Stop solution 2N H2SO4 ; Carl Roth GmbH & Co. KG, 
Karlsruhe, Germany 
Thrombin (Human) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Thrombin (Mouse) Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
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Tinzaparin Innohep®, LEO Pharma A/S; Ballerup, 
Denmark. 
Trypsin EDTA Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
VEGF165 (Human) R&D Systems, Wiesbaden, Germany. 
Kits  
ADAMTS13 screening assay kit Technoclone GmbH, Vienna, Austria 
PCR-Kit SYBR Green PCR Kit, Qiagen N.V.; Hilden, 
Germany. 
Proteome Profiler-kit Proteome Profiler Mouse Angiogenesis Array 
Kit, R&D Systems, Inc., Minneapolis, MN, 
USA. 
Reverse Transcription Kit 
 
QuantiTect Reverse Transcription Kit, Qiagen 
N.V.; Hilden, Germany. 
RNA isolation-Kit RNeasy Mini Kit, Qiagen N.V.; Hilden, 
Germany. 
VEGF-A-ELISA-Kit DuoSet® ELISA Development Systems, R&D 
Systems, Inc., Minneapolis, MN, USA. 
 
3.1.5 Cell culture materials 
 
Material Product reference 
12-well flat bottom with lid Falcon®, Becton, Dickinson and Co. (BD), NJ, 
USA. 
24-well flat bottom with lid Falcon®, Becton, Dickinson and Co. (BD), NJ, 
USA. 
Cell culture flask T75 Falcon®, Becton, Dickinson and Co. (BD), NJ, 
USA. 
Cell culture flasks T25 Falcon®, Becton, Dickinson and Co. (BD), NJ, 
USA. 
Cell culture inserts ThinCert™ 24Well, Greiner Bio One 
International GmbH 
Cell strainer (20 µm diameter) Merck & Co., Inc., New Jersey, USA. 
Coverslips Ø 20 mm Menzel-Gläser, Thermo Fisher Scientific 
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Gerhard Menzel B.V. & Co. KG; 
Braunschweig, Germany. 
Cryovial (2 ml) Thermo Fisher Scientific, Waltham, USA. 
Dulbecco's Modified Eagle's Medium (DMEM) Merck & Co., Inc., New Jersey, USA. 
Endothelial Cell Growth Medium-2 (EGM™-2) Lonza Group AG, Basel, Switzerland. 
Endothelial Cell Medium (ECM) ScienCell, Carlsbad, USA. 
Fetal bovine serum (FBS) Boehringer Mannheim, Mannheim, Germany. 
Human Fibronectin Sigma-Aldrich, Inc.; St. Louis, USA. 
Medium 199 (M199) Gibco-Thermo Sicentific, Waltham, USA. 
Neubaur cell counter Neubauer bright line, Paul Marienfeld GmbH & 
Co. KG, Lauda-Königshofen, Germany. 
Porcine Gelatin Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Roswell Park Memorial Institute-Medium 
(RPMI) 
Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
Trypsin EDTA Sigma-Aldrich Biochemie GmbH, Hamburg, 
Germany. 
µ-Slide 0.2 Luer Ibidi GmbH, Munich, Germany 
 
3.1.6 Primers 
 
Targeted gene Sequence 
VWF Forward 5’-TGGTGCAGGATTACTGCGGC-3’ 
 Reverse 5’-GCTTTGCCCAGCAGCAGAAT-3’ 
PAR-1 Forward 5’-CCTGCTTCAGTCTGTGCGG-3’ 
 Reverse 5’-CTGGTCAAATATCCGGAGGCA-3’ 
VEGFR-1 Forward 5’-GCAAAGCCACAACCAGAAG-3’ 
 Reverse 5’-ACGTTCAGATGGTGGCCAAT-3’ 
VEGFR-2 Forward 5’-CGTGTCTTTGTGGTGCACTG-3’ 
 Reverse 5’-GGTTTCCTGTGATCGTGGGT-3’ 
P-Selectin Forward 5’-CGTGGAATGCTTGGCTTCTG-3’ 
 Reverse 5’-TGAGCGGATGAACACAGTCC-3’ 
Ang-2 Forward 5’-CCTGTTGAACCAAACAGCGG-3’ 
 Reverse 5’-AACAGTGGGGTCCTTAGCTG-3’ 
ß-Actin Forward 5’-AGAAAATCTGGCACCACACC-3’ 
 Reverse 5’-CCATCTCTTGCTCGAAGTCC-3’ 
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3.1.7 Antibodies 
 
Primary antibodies 
Working 
concentration 
Incubation 
period 
Product reference 
Mouse anti-Human CD 31
  
1:75 Overnight M0823, Dako 
Denmark A/S; 
Glostrup, Denmark. 
Mouse anti-Human TSP 1:75 120 minutes Laboratory Vision/ 
Neomarkers 
Rabbit anti-Human VWF 1:150 120 minutes A0082, , Dako 
Denmark A/S; 
Glostrup, Denmark. 
Rat anti-Mouse CD31 1:75 Overnight 550274, BD 
Pharmingen, 
Rat anti-Mouse CD42b 1:75 120 minutes M042-0, EMFRET 
Analytics, 
Sheep FITC-conjugated 
anti-Human/Mouse 
1:150 90 minutes GTX28822, GeneTex, 
Inc, Irvin, USA 
Secondary antibodies    
Alexa Fluor® 488 Donkey 
anti-Sheep IgG 
1:200 60 minutes A11015, Invitrogen, 
Darmstadt, Germany. 
Alexa Fluor® 555 Goat anti-
Mouse IgG 
1:200 60 minutes A21422, Invitrogen, 
Darmstadt, Germany. 
Alexa Fluor® 555 Goat anti-
Rabbit IgG 
1:200 60 minutes A21428, Invitrogen, 
Darmstadt, Germany. 
Alexa Fluor® 555 Goat anti-
Rat IgG 
1:200 60 minutes A21434, Invitrogen, 
Darmstadt, Germany. 
FITC Goat anti-Rabbit IgG 1:200 60 minutes 554020, Becton, 
Dickinson and 
Company (BD), NJ, 
USA. 
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FITC Goat anti-Rat IgG 1:200 60 minutes 554016, Becton, 
Dickinson and 
Company (BD), NJ, 
USA. 
Rabbit anti-Human 
VWF/HRP 
1:200 60 minutes P0226, Dako Denmark 
A/S; Glostrup, 
Denmark. 
 
3.1.8 Consumables 
 
Product description Product reference 
Cell strainer (20 µm diameter) Merck & Co., Inc., New Jersey, USA. 
ELISA-Microplate (96-Wells) Nunc MaxiSorp®, Affymetrix, Inc.; Santa 
Clara, USA. 
 Filter tips: 10, 20, 200, 1000 μl epTIPs Dualfilter, Eppendorf Research® plus, 
Eppendorf AG; Hamburg, Germany. 
Needles (20G) Falcon®, Becton, Dickinson and Co. (BD), NJ, 
USA. 
Object slide 25 x 75 x 1 mm3 Menzel-Gläser Superfrost Plus, Thermo 
Fisher Scientific Gerhard Menzel B.V. & Co. 
KG; Braunschweig, Germany 
Polypropylene tubes 15 ml Falcon®, Becton, Dickinson and Company 
(BD), Franklin Lakes, NJ, USA. 
Polypropylene tubes 5 ml Falcon®, Becton, Dickinson and Company 
(BD), Franklin Lakes, NJ, USA. 
Polypropylene tubes 50 ml Falcon®, Becton, Dickinson and Company 
(BD), Franklin Lakes, NJ, USA. 
Safe lock tubes: 0.5, 1.5 and 2 ml Eppendorf Research® plus, Eppendorf AG; 
Hamburg, Germany. 
Serological pipettes (5, 10 and 25 ml) SARSTEDT AG & Co. KG, Nümbrecht, 
Germany. 
Syringes (1 ml and 20 ml) Becton Dickinson (BD) and Co., New Jersey, 
USA. 
Tips 10, 20, 200, 1000 µl epT.I.P.S®, Eppendorf AG; Hamburg, 
Germany. 
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3.1.9 Software 
 
Product description Source 
Fiji/ImageJ NIH, USA 
GraphPAd Prism GraphPad Software, Inc. USA 
Inkscape vector graphic editor Inkscape. Open source. inkscape.org 
Light Cycler ® 96 Software 1.1 Roche Life Sciences, Mannheim, Germany. 
Mendeley Mendeley Ltd.,UK 
Microplate Software Gen 5 V1.3 BioTek Instruments, Inc; Winooski, VT, USA. 
Microsoft Ofice™ Microsoft Corporation, Washington, USA. 
Nano drop 2000 Thermo Fisher Scientific, Waltham, USA. 
PlateletWeb Systems Biology Workbench. University of 
Würzburg 
Zeiss Zen Microscope Software Zeiss, Jena, Germany 
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3.1.10 Cell lines 
 
HUVEC: Primary human umbilical vein endothelial cells (HUVECs) were isolated 
from umbilical cords as it was previously described (Kerk et al. 2010). 
HBMEC: Primary human microvascular endothelial cells (HBMECs) were purchased 
from ScienCell #1000 (USA). 
bEND3: The murine immortalized brain endothelial cell line bEND3 was purchased 
from ATCC Genuine Cultures® CRL-2299™ (USA). 
Ret cells: Ret melanoma cells (Ret cells) kindly provided by Prof. Viktor Umansky, 
from the Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, 
Germany. Ret cells were originally isolated from skin tumors from ret transgenic mice 
(Zhao et al. 2009) 
 
3.1.11 Animals 
 
Our animals were maintained under specific pathogen-free conditions and all 
experiments were performed according to a protocol approved by the governmental 
animal care authorities. Permission numbers for animal experimentation: AZ: 35-
9185.81/G-206/16 and G-220/16. 
The Wild type C57BL/6J (Wt) mice were purchased from the Jackson Laboratory 
(USA). 
VWF deficient (VWF KO) mice with C57BL/6 background were originally purchased 
from the Jackson Laboratory (USA) and maintained in our own breeding facility. 
The ret transgenic mouse (ret) was kindly provided by Prof. Viktor Umansky from 
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. 
These animals with a C57BL/6 background overexpress the human ret transgene in 
melanocytes. Its expression is regulated by mouse metallothionein-I promotor-
enhancer (Kato et al. 1998). The ret mice develop spontaneously cutaneous 
melanoma with metastases in different organs such as lymph nodes, lungs, liver, 
brain and the bone marrow (Umansky and Sevko 2013), resembling the malignant 
melanoma disease in humans. 
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3.2 Methodology 
 
3.2.1 Cell culture 
 
3.2.1.1 Culture initiation 
All cells were seeded in T25 or T75 flasks as monocultures and maintained under 
culture conditions, in a humidified atmosphere at 37°C and 5% CO2. All the work 
involving cellular material was carried out under strict sterile conditions. To this end, 
all cells were manipulated within a laminar flow bench previously decontaminated 
with 70% ETOH. Cell monitoring was performed daily and the nutrient medium was 
changed every two days: 
HUVECs were grown in a 0.5% Gelatin (Sigma-Aldrich) coated surface in a complete 
culture medium containing two thirds of M199 (Life Technologies), supplemented with 
2% of fetal bovine serum (FBS), hydrocortisone (200 ng/ml culture medium solution), 
0.5 ng/ml VEGF, 10 ng/ml human FGF-2, 5 ng/ml human epidermal growth factor 
(EGF), 20 ng/ml human IGF-1, and 1 μg/ml ascorbic acid and one third of EGM2 
(LONZA). HUVECs were daily monitored and maintained under culture conditions 
(95% humidity, 37° C, and 5% CO2). Only passages lower than 6 were used for all 
experiments. 
HBMECs were grown in a 10 µg/ml Fibronectin (Sigma-Aldrich) coated surface in 
Endothelial Cell Medium (ECM) (ScienCell) supplemented with 5% FBS (ScienCell), 
1% endothelial cell growth supplements and 1% penicillin/streptomycin solution 
(ScienCell). HBMECs were daily monitored and maintained under culture conditions 
(95% humidity, 37° C, and 5% CO2). Only passages lower than 5 were used for all 
experiments. 
The murine brain endothelial cell line bEND3 was grown in a 0.5% Gelatin coated 
surface in Dulbecco's Modified Eagle's Medium (DMEM) (Merck) supplemented with 
10% FBS. bEND3 were daily monitored and maintained under culture conditions 
(95% humidity, 37° C, and 5% CO2). Only passages lower than 20 were used for all 
experiments 
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The murine melanoma Ret cells were grown in RPMI (Sigma-Aldrich) containing 10% 
FBS, 2 mM L-glutamine, 1% nonessential amino acids and 1% Penicillin-
Streptomycin. Ret cells were daily monitored and maintained under culture conditions 
(95% humidity, 37° C, and 5% CO2). Only passages lower than 20 were used for all 
experiments. 
 
3.2.1.2 Cell passaging 
 
After reaching a confluency of 80-90% they were either passaged, transferred to the 
assay systems or cryopreserved. 
For cell detachment cell monolayers were firstly rinsed with 5 ml of PBS and then 
incubated with 1 ml of Trypsin-EDTA solution (Sigma-Aldrich) under culture 
conditions (95% humidity, 37° C, and 5% CO2) for 2-5 minutes. Cell detachment was 
confirmed under the microscope, when more than 90% of the cells were detached 5 
ml of complete medium was added to stop the trypsin. Cell suspension was then 
transferred into a 15 ml conical bottom tube and cell density was determined using a 
Neubauer counting chamber (to discern between living and dead cells 1:10 Trypan 
blue was added into a 10 µl cell suspension and living cells were colorized in blue). 
The total number of cells per milliliter was calculated by this formula: 
(Counted living cell number / number of counted chambers) * 104 * dilution factor. 
Then, the cell suspension was centrifuged at 300 x g for 5 minutes. After 
centrifugation, the supernatant was discarded and the cell pellet resuspended in the 
corresponding volume with complete medium or in complete medium supplemented 
with 10% DMSO  and 10% FBS for cryopreservation. 
 
3.2.1.3 Ret melanoma cell supernatant 
 
For the generation of Ret cell supernatant (Ret Sn), Ret cells were grown in a T75 
flask with complete RPMI medium. When the confluence was reached, the medium 
was removed and cell monolayer rinsed three times with 10 ml of PBS. Then Ret 
cells were incubated for 8 hours with 5 ml of HRBS under culture conditions (95% 
humidity, 37° C, and 5% CO2). After the starvation, cell supernatant was transferred 
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into a 15 mL conical bottom tube and centrifuged at 300 x g for 5 minutes. Next, the 
supernatant was collected and transferred into 1.5 ml tubes. Ret Sn was then stored 
at -20° C and used within the following 3 months. 
 
3.2.1.4 Endothelial cell stimulation 
 
Endothelial cells (ECs) were seeded on coated coverslips in a 12-well plate. 500 µl of 
complete medium with 100*103 cells was added in each well. Next day, medium was 
substituted with fresh complete medium and cells were grown until confluence under 
culture conditions (95% humidity, 37° C, and 5% CO2). 
Before stimulation, each well was washed once with 500 µl of HBRS. As a negative 
control, endothelial cells were incubated with 500 µl HBRS (Vehicle). As positive 
controls, ECs were incubated with 0.5 U/ml of thrombin or with 2500 pg/ml Vascular 
endothelial growth factor-165 (VEGF165) diluted in HBRS as it was described in 
Desch et al. 2012. Additionally, cells were also incubated with 500 µl Ret Sn. To 
examine the inhibitory effect of distinct molecules, preincubation with Tinzaparin 
(100U/ml), Fondaparinux (50 µg/ml) or Bevacizumab (0.65 mg/mL) was applied for 
30 minutes before the administration.  
After 15 minutes of incubation under culture conditions (95% humidity, 37° C, and 5% 
CO2) 450 µl of the supernatant was collected and transferred into 1.5 ml Tubes 
coated with 50 µl of 4% BSA. Supernatants were analyzed directly by ELISA or 
stored at -20°C for their analysis in the following days. 
 
3.2.1.5 Enzyme-linked Immunoabsorbent Assay (ELISA) 
 
ELISAs for VWF were performed to quantify the release of VWF in the supernatant of 
stimulated ECs and in the plasma of cancer patients. 
96-well ELISA microplate was coated with the capture antibody Rabbit anti-human 
VWF (Dako) diluted in PBS (1:500) and incubated overnight at 4° C. Next day, 
coated wells were washed with PBS-T and incubated with 4% BSA for one hour at 
37° C in order to block the unspecific binding sites. In the meantime, the samples 
were thawed at room temperature (RT) and the standard samples prepared by serial 
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dilutions of human plasma pool with a determine VWF content. After blocking, the 
microplate was washed three times with PBS-T and samples were loaded (100µl per 
well) and incubated for 1 hour at 37°C. Next, the microplate was washed three times 
with PBS-T and incubated for 1 hour at 37°C with the secondary antibody, HRP-
rabbit anti-human VWF (Dako) in PBS-T (1:4000). After the incubation, microplate 
was washed three times with PBS-T. Next, microplate was loaded with the Substrate 
solution (1:1 mixture of Color Reagent A and Color Reagent B, R&D System) and 
incubated for 20 minutes. Then, the reaction was stopped by using the Stop solution 
(2N H2SO4).The optical changes were determined in each well at 450 and 540 nm 
using a microplate reader (BioteK PowerWave XS2 photometer). 
 
3.2.1.6 Immunofluorescence staining 
 
Cells seeded on 20 mm coverslip were washed twice with HEPES and, depending on 
the antibodies, cells were fixed with methanol for 30 minutes at -20°C or with 4% 
PFA for 30 minutes at 4°C. After fixation, cells were washed three times with HEPES 
and incubated for 1 hour with Blocking buffer I (HEPES containing 0.3% TritonX-100 
(Sigma) and 2% of BSA). After the blocking, cells were washed with Incubation buffer 
(HEPES containing 0.3% TritonX-100) and incubated with the primary antibody 
diluted in Incubation buffer. After primary antibody incubation, cells were washed 
three times with Incubation buffer and secondary antibody incubation was performed 
as it was described before. Working concentrations of the antibodies and the 
incubation times were implemented following the instructions of the manufacturers 
(3.1.7 Antibodies). Whether a secondary antigen was required to be stained, the 
cells were blocked again for 30 minutes and the staining procedure was repeated as 
before. To stain the nuclei, cells were incubated with DAPI diluted in PBS (1: 1000). 
Coverslips were then thoroughly washed twice with PBS and once distilled water. 
Finally, coverslips were mounted on object slides with 30 μl of DABCO-Mowiol and 
stored overnight at 4°C. 
Images from the staining were obtained by using the Z1 AxioObserver inverted 
fluorescence microscope (Carl Zeiss). 
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3.2.1.7 Quantitative real-time polymerase chain reaction 
 
To examine the genetic signature of ECs quantitative real-time polymerase chain 
reactions (qRT-PCR) technique was applied as follows: 
RNA was isolated from confluent EC cultures using the RNeasy Mini Kit (Qiagen). 
The procedure was performed following the instructions provided by the 
manufacturers. Briefly, ECs were lysed with RLT lysis buffer (Qiagen) containing 1 % 
of 2-Mercaptoethanol. The cell lysate was transferred to an RNeasy column, where 
RNA was purified after being washed and treated with DNases. The purified-RNA 
was eluted and its purity was calculated with a NanoDrop™ 2000/2000c 
Spectrophotometer. For long term storage RNA was stored at -20°C. 
Next, cDNA was generated using the Qiagen´s QuantiTect Reverse Transcription Kit. 
In accordance to the instructions of the manufacturers 500 ng of isolated RNA was 
incubated with a master mix (1µl of Quantiscript Reverse Transcriptase, 4µl of 
Quantiscript RT buffer 5X and 1µl of RT Primer Mix) for 15 min at 42° C. To 
inactivate the reverse transcriptase a second incubation for 3 minutes at 95°C was 
performed. The resulting cDNA was diluted 1:10 in RNase-free water and stored at -
20° C. 
Finally polymerase chain reaction (PCR) was carried out in accordance to the 
Qiagen's QuantiFast SYBR Green PCR Kit protocol. Primers described in the section 
3.1.6 were used to amplify the targeted genes. The reaction took place in a 96-well 
PCR plate loaded as follows: 
Components Volume/well 
RNase-free water Variable (up to 25 µl) 
Primers (Forward + Reverse) 5 µg 
cDNA 100 ng 
(volume depends on sample concentration) 
QuanitFast SYBR Green PCR 
Master Mix 
12.5 µl 
Total volume 25 µl 
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The PCR cycles took place in a thermocycler under the following conditions: 
Step 1. Time Temperature 
PCR initial activation step 5 min 95° C 
Step 2.Two-step cycle 
Denaturation 10 seconds 95° C 
Combined/annealing/extension 30 seconds 60° C 
Number of cycles Between 30-40 depending in the amount of 
template DNA) 
 
3.2.2 Ex vivo examination of platelets 
 
3.2.2.1 Platelet and erythrocytes isolation 
 
Blood was drawn from a forearm vein of healthy donors or from the inferior cava vein 
of mice as was previously described (Parasuraman, Raveendran, and Kesavan 
2010). The blood was anticoagulated with 3.2% of sodium citrate buffer (SARSTETD 
AG& Co.) and kept for 30 minutes at room temperature (RT). Then, citrated blood 
was centrifuged at 180 x g for 15 minutes without break. Upon centrifugation the 
resultant blood was stratified in three phases: The first one, formed by the platelet 
rich plasma (PRP) which contains plasmatic proteins and platelets. Secondly an 
interphase identified as the “buffy coat” where leukocytes are deposited. The third 
phase is composed by erythrocytes. 
PRP was then gently transferred into a 15 ml conical bottom tube containing of 1:1 
Washing Buffer supplemented with 1 U/ml of the platelet inhibitor Apyrase. 
Importantly, the pH of the Washing Buffer was previously stablished at 6.6 to avoid 
platelet activation (Scharbert et al. 2011).Then, platelet suspension was centrifuged 
at 1200 x g; 15 minutes; without breaks. The resulting supernatant was discarded 
and the platelet-pellet was resuspended in Resuspension buffer with a physiological 
pH of 7.4 (Scharbert et al. 2011). Note that either the Washing or the resuspension 
buffers lack of calcium (3.1.3 Buffers and solutions). For an adequate activation of 
the internal signalling calcium ions must be provided, thus CaCl2 was added to a final 
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concentration of 1 mM (Paniccia et al. 2015). 
To obtain a physiological haematocrit for our in vitro perfusion assays, erythrocytes 
from citrated blood were also isolated. The erythrocyte pellet obtained from the 
citrated blood was transferred into a 50 ml conical tube and washed with PBS (1:1). 
Then erythrocytes were centrifuged at 800 x g for 10 minutes. The supernatant and 
buffy coat was aspirated and the same procedure was repeated. In a final washing 
step erythrocytes were washed with HEPES (1:1) and centrifuged at 800 x g for 10 
minutes. The resulting supernatant was aspirated obtaining a pure pellet of washed 
erythrocytes. 
 
3.2.2.2 Light transmission aggregometry 
 
The light transmission aggregometry (LTA) technique was used to study the effect of 
different platelet agonists on platelet aggregation in vitro. In our experiments stirred 
suspensions of washed platelets (3.2.2.1) were exposed to collagen type I (50 
µg/ml), histamine (100 µM) or thrombin (0.5 U/ml) and subsequent formation of 
platelet aggregates was monitored by a CHRONO-LOG® Model 700 (Chrono-log 
Corporation, Hawertown, USA). 
To test the impact of different drugs on platelet aggregation, preincubation of 
platelets with Tinzaparin (100 U/ml) or Fondaparinux (50 µg/ml) was implemented 
before the addition of the agonists. 
 
3.2.2.3 Generation of platelet-derived supernatant 
 
Platelets secrete many proinflamatory and procoagulatory factors stored in α 
granules and dense granules (Golebiewska and Poole 2015) To analyze the platelet 
secretome, we induced the activation of platelets and harvested the resulting platelet 
releasates. 
Washed platelets, isolated as described before in the section 3.2.2.1, were activated 
by the addition of the platelet agonists thrombin (0.5 U/ml) or collagen type I (50 
µg/ml) for 15 minutes. Next, platelet activation was stopped by adding 1:1000 
prostaglandin-1 (PGE-1) and platelets were centrifuged at 1200 x g for 15 minutes 
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without brakes. The supernatant was carefully harvested avoiding the contact with 
the platelet-pellet. Platelet supernatant was used directly or stored at -20°C. To test 
the effect of different inhibitors on the platelet secretome, washed platelets were 
incubated for 30 minutes with Tinzaparin (100 U/ml), Fondaparinux (50 µg/ml) or 
Bevacizumab (0.65 mg/mL) prior their activation. 
 
3.2.2.4 Platelet-derived vascular endothelial growth factor A secretion 
 
ELISAs for vascular endothelial growth factor A (VEGF-A) secretion in platelet 
releasates was performed by using the Quantikine® ELISA kits (R&D Systems). The 
assay procedures were carried out in accordance to the instructions provided by the 
manufacturers. 
 
3.2.2.5 In vitro perfusion assays 
 
Microfluidic assays (ibidi GmbH) were implemented to study in real time and under 
specific flow conditions the formation of a micro-thrombus.. 
A µ-Slide 0.2 Luer channel was coated with 0.5% Gelatin. Then, 0.4 x 106 ECs 
(HUVECs, HBMECs or bEND3) were homogeneously dispensed along the 
microchannel. The microfluidic slides containing ECs were maintained under culture 
conditions (95% humidity, 37° C, and 5% CO2) and the medium was replaced every 
with fresh equilibrated medium (37° C and 5% CO2). The formation of a confluent 
monolayer within the microchannel was monitored under the microscope every day; 
usually confluence was achieved two days after the seeding. 
When the monolayer was formed, the Perfusion Set was mounted onto the 
Microfluidic slide and both were placed together in the Microscope incubation 
chamber which maintains the cells under cell culture conditions (95% humidity, 37° 
C, and 5% CO2). Then the microfluidic slide was perfused with a 4 ml mixture buffer 
containing HBRS, 25% hematocrit and 15% platelets. Shear rate was set at 2.5 
dyn/cm2 to mimic the shear stress of brain microvessel (Nicolay et al. 2018). 
In order to examine the impact of EC activation on platelet adhesion 100 μM 
histamine was added through the Perfusion Set. In a second step, platelet activation 
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was induced by addition of the platelet agonist collagen type I (50 µg/ml) in 
combination with a FITC-conjugated sheep anti-mouse VWF antibody (1:100; 
GeneTex Inc) for the visualization of VWF. Platelet attachment and aggregation was 
recorded in real time using using a Zeiss AxioObserver Z1 equipped with an 
AxioCam MRc (Carl Zeiss AG, Oberkochen, Germany). 
 
3.2.2.6 Transmigration assay 
 
A transwell migration assay was performed to test the migratory response of Ret cells 
in presence of platelet-derived supernatant. 
 
 
Figure 11. Schematic diagram of the transmigration assay: Ret melanoma cells were co-
incubated for 8 hours with the supernatant of resting platelets (rest Plt Sn) or collagen type I-
activated platelets (act Plt Sn) with or without incubation with Tinzaparin (100 U/ml) or 
Bevacizumab (0.65 mg/mL) (act Plt Sn +Tinza/Bevac). Then, upper chambers were removed 
and transmigrated tumor cells counted after 24 hours. 
 
To this end 0.12x106 HBMECs were seeded in the inner well of a Transwell system 
and grown for 72 hours under cell culture conditions (95% humidity, 37° C, and 5% 
CO2). Then, Ret cells were harvested and labeled with 1:1000 CellTrace™ Calcein 
Green (Invitrogen) for 10 minutes. After labeling, Ret cells were centrifuged at 500 x 
g for 5 minutes, and resuspended in RPMI without supplements (Harvesting 
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medium). Then inner wells were loaded with 20*103 labeled Ret cells supplemented 
with 200µl of platelet supernatant. After 8 hours of coincubation, inner wells were 
removed and transmigrated Ret cells adhered to the bottom of the outer well were 
counted after 24 hours. 
 
3.2.2.7 Transendothelial electrical resistance 
 
The transendothelial electrical resistance (TEER) is the measurement of the electrical 
resistance across a cellular monolayer and is considered a reliable indicator of the 
integrity and permeability of a cellular barrier (Srinivasan et al. 2015). To examine the 
impact of platelet activation on the integrity of brain endothelium, we monitoring the 
impact of platelet releasates on the TEER of a HBMEC monolayer by using 
Endothelial Substrate Impedance Sensing (ECIS) arrays (Applied BioPhysics Inc., 
NY USA). 
HBMECs were seeded into coated 8-well ECIS slides (8W1E PET; Applied 
BioPhysics Inc., NY, USA) at a concentration of 1x105 cells/ well. The electrical 
resistance at a frequency of 4,000 Hertz was measured every 48 seconds by ECIS-
zeta system software (Applied BioPhysics Inc., NY, USA) while cells grew under cell 
culture conditions (95% humidity, 37° C, and 5% CO2). After 72 hours ECs reached 
their confluence, reflected by the stabilization of TEER values. The impact of the 
supernatant of resting platelets or platelets activated with collagen type I (50 μg/ml) 
with or without preincubation with Tinzaparin (100 U/ml) or Bevacizumab (0.65 
mg/mL) on TEER was measured for 24 hours. 
 
3.2.3 Human samples 
 
In accordance with the Declaration of Helsinki and the International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) guidelines an informed written consent was obtained from all 
participants  
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3.2.3.1 Human blood samples 
 
Blood samples from cancer patients were anticoagulated with 3.2% of sodium citrate 
buffer (SARSTETD AG& Co.) and kept for 30 minutes at room temperature (RT). 
Then, samples were centrifuged at 1000 x g for 5 minutes and the citrate plasma was 
collected in 2 ml Tubes and stored at -70°C.  
 
3.2.3.2 ADAMTS13 activity measurements 
 
ADAMTS13 activity was evaluated in the citrate plasma of cancer patients by a 
commercially available kit according to the instructions of the manufacturer 
(TechnocloneGmbH).  
 
3.2.3.3 Concentration of plasmatic von Willebrand factor in cancer patients 
 
Plasmatic levels of VWF was quantified using a sandwich enzyme-linked immuno- 
sorbent assay (ELISA) technique as described before (section 3.2.1.5) 
 
3.2.3.4 Tissue samples 
 
Tissue samples from human metastatic brains were obtained from the Neurosurgery 
department of the Medical Faculty of Mannheim. 
Tissue was directly embed in Tissue-Tek® (Sakura Finetek) and placed on dry ice for 
freezing. Frozen tissue samples were stored in -80° C until they were cryosectioned 
as is explained afterwards (section 3.2.4.3) 
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3.2.4 Animal models 
 
3.2.4.1 Impact of anticoagulant therapy with Tinzaparin on platelet activation 
 
To determine the effect of Tinzaparin on platelet activation in the context of brain 
metastasis, 8- to 12-weeks ret mice were subcutaneously treated for 100 days with 
0.6 U/g of Tinzaparin (innohep; Leo Pharma) or saline solution (NaCl) as it was 
described before (Bauer, Suckau, Frank, Desch, Goertz, Wagner, Hecker, Goerge, 
Umansky, Beckhove, Utikal, Gorzelanny, Diaz-valdes, et al. 2015)  
 
3.2.4.2 Impact of anticoagulant therapy with Tinzaparin on brain metastasis 
formation 
 
In order to confirm the direct impact of Tinzaparin on brain metastasis formation an 
alternative mouse model of brain metastasis was applied by Prof. Winkler’s group 
from Experimental Neurooncology, German Cancer Research Center (DKFZ), 
Heidelberg, Germany. This model consisted on the injection of 5x105 A2058 (ATCC® 
CRL11147™) melanoma cells in 100 μl of PBS into the left cardiac ventricle of 8- to 
12-week-old male NMRI-nu/nu mice (≥20 g, Charles River Germany) previously 
anesthetized with ketamine/xylazine. A group of animals received daily a 
subcutaneous injection of 0.6 U/g of tinzaparin (innohep; Leo Pharma) from day -2 
(before tumor cell intracardiac injection) until day +31 (after tumor cell intracardiac 
injection). 
 
3.2.4.3 Brain cryosectioning 
 
When the in vivo experiments were terminated mouse brains were rapidly harvested 
under sterile conditions: 
Head skin was pulled away and exposed skull was disinfected with 70% ETOH. 
Then, using sterile surgical scissors the skull was open by a scission from the 
foramen magnum along the midline until the end of the frontal bone. Thereafter, the 
parietal bones were removed and the brain was harvested after cutting the brain 
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steam at the base of the brain. Then, brains were immediately embedded in Tissue-
Tek and placed on dry ice for freezing. 
Frozen tissue embedded in Tissue-Tek ® was cryosectioned (10 µm coronal 
sections) at -20°C using the high precision microtome (Kryostat CM 1900). Sections 
were picked up on object slides and dried out for 1 hour at RT and stored at -20°C. 
 
3.2.4.4 Immunohistochemistry 
 
For immunohistochemical analyses cerebral coronal cryosections of 10 μm of 
thickness were 130 μm apart to avoid extensive overlapping of metastases over 
several slices. Plain hematoxylin and eosin (H&E) staining was used to analyze 
cerebral metastases. Image acquisition was performed via slide scanner (Axio 
Scan.Z1; ZEISS) in brightfield configuration with a 20x/0.8 Plan-Apochromat 
objective (ZEISS) and a Hitachi HV-F202SCL camera. 
 
3.2.4.5 Immunofluorescence  
 
Tissue cryosections were dried for 30 minutes at room temperature (RT). Then, they 
were fixed for 30 minutes with methanol at -20° C or with 4% PFA at 4° C, depending 
on the specifications provided by the manufacturers. Next, sections edges were 
delimited with FixoGum (Marabu Fixogum®) and washed three times with PBS. 
Thereafter, the tissue sections were blocked with Blocking buffer II (10% goat serum 
in PBS-T) for 90 minutes. After the blocking, the sections were washed once with 
PBS and incubated with the primary antibody diluted in PBS-T (working concentration 
as well as incubation time was performed according to the instructions of the 
manufactures). In order to reveal whether the secondary antibody may show non-
specific bindings, negative control sections were incubated only with PBS-T. After 
washing three times with PBS-T, sections were incubated with the secondary 
antibody diluted in the Blocking buffer II (working concentration as well as incubation 
time was performed according to the instructions of the manufacturers; 3.1.7 
Antibodies). From now on, all steps were performed under dark conditions to 
prevent bleaching. When a second structure was required to be stained, the cells 
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were blocked again for 30 minutes and the same staining procedure was repeated. 
For nuclei staining, sections were incubated with 1: 1000 DAPI in PBS. Finally, the 
tissue sections were washed thoroughly with PBS and distilled water, then sections 
were capped with 40 µl of DABCO-Mowiol and covered by 24x60 mm coverslip. 
Slides were stored at 4°C for a short term and at -20°C for long storage. 
Images from the staining were obtained by using the Z1 AxioObserver inverted 
fluorescence microscope (Carl Zeiss). 
 
3.2.4.6 Fibrinogen binding assay 
 
To identify activated platelets in tissue sections, an in situ fibrinogen binding assay 
was performed. Tissue sections were incubated with 100µl (20µg/ml) of Alexa 488-
conjugated fibrinogen (Thermo Fisher Scientific) for two hours at RT, in a humidified 
atmosphere. 
Next, sections were washed with PBS and fixed with 4% PFA for 30 minutes at 4°C. 
Thereafter, tissue sections were stained for the platelet marker CD42 (EMFRET) 
following the procedure previously described in the section 3.2.3.7. 
Images from the fibrinogen binding assay were obtained by using the Z1 
AxioObserver inverted fluorescence microscope (Carl Zeiss). 
 
3.3 Statistical analysis 
 
Data are presented as the mean ± standard deviation (SD) of a number of 
independent experiments specified in each section. GraphPad Prism. Version 8.1.0. 
was used to determine the significance of the results. To compare the differences 
between two groups of data Two-Tailed, Student T-test was implemented. When 
more than two groups were compared, Two way ANOVA, Bonferroni post-test was 
implemented. And F-test was used to analyze the differences among linear results. 
Significance was assumed only when *, P < 0.05, **, P < 0.01. 
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4. Results 
 
4.1 Distinct expression of von Willebrand factor in brain 
microvascular endothelial cells 
 
4.1.1 Brain microvascular endothelial cells express low amounts of 
VWF 
 
In order to characterize the expression of VWF in macro- and microvascular 
endothelial cell (ECs) systems an immunofluorescence staining for VWF and the 
endothelial cell marker CD31 was performed on primary human umbilical vein 
endothelial cells (HUVECs) and primary human brain microvascular ECs (HBMECs).  
HUVECs, as well as HBMECs exhibited the characteristic distribution of CD31 at the 
lateral borders of ECs (Cheung et al. 2015). Besides, both cell types exhibited the 
typical punctuate distribution of VWF within intracellular storage granules, indicative 
of quiescent ECs storing VWF in Weibel-Palade bodies (WPBs) (Figure 12 A and 
B). However, clear differences in the abundance of VWF were detected between 
HUVECs and HBMECs. The percentage of VWF positive cells was significantly lower 
in HBMECs (26.22 ± 3.12%) compared to HUVECs (76.80 ± 19.55%) (Figure 12 C). 
Additionally, the mean number of intracellular VWF storage granules (WPBs) per cell 
was calculated by using ImageJ/Fiji Software (NIH) and the corresponding 
quantification showed that compared to HUVECs (123 ± 27) the number of WPBs 
was notably reduced in HBMECs (70 ± 15)  (Figure 12 D). This finding suggests that 
VWF is heterogeneously expressed among the different EC populations. 
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Figure 12. Distinct abundance of VWF in HUVECs and HBMECs. A and B. Confluent 
HUVECs (A) and HBMECs (B) were stained for VWF (green), the endothelial cell marker 
CD31 (red) and DAPI (blue) for nuclei. Both cell types exhibit a regular distribution of EC 
markers: CD31 is concentrated at the cell borders and VWF shows a punctuate distribution 
in ECs, depicted by green rod-shaped structures in the cytosol. C and D. The percentage of 
cells containing intracellular VWF (C) and the number of VWF storage granules (WPBs) per 
cell (D) were quantified in HUVECs and HBMECs by using ImageJ/Fiji Software (NIH) (n = 
1000-2000 cells/group from 3 independent experiments); *, P < 0.05, **, P < 0.01 (two tailed, 
Student's t-test). Data are presented as mean ± SD. Scale bar: 50 µm. 
 
4.1.2 Heterogeneous distribution of VWF in brain microvasculature 
 
For an in vivo validation of the previous findings, VWF expression was analyzed in 
the brain vasculature of wild type mice (Wt). For this purpose brain cryosections of 
Wt mice were stained for VWF (green), CD31 (red) and DAPI (blue).  
The analysis of immunofluorescence staining reactivity revealed that VWF was 
almost absent in vessels with small diameter (< 10 µm) (Figure 13 A). In bigger 
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vessels (10-50 µm), VWF reactivity increases considerably, but still showed an 
incomplete mosaic-like VWF staining pattern (Figure 13 B). Only in vessels with 
large diameter (> 50 µm) a clear and strong VWF staining was detected in the vessel 
walls (Figure 13 C). These observations suggested a marked regulation of VWF 
expression with regard to the vessel diameter. To confirm this, the abundance of 
VWF was quantified by using ImageJ/Fiji in more than 500 brains vessel grouped by 
their diameter. The correlation analysis demonstrated a positive correlation between 
VWF abundance and vessel diameter (Figure 13 D) and significant differences 
among the groups (Table 2).  
 
Figure 13. Immunofluorescence staining of VWF in the brain vasculature. Brain 
cryosections of Wt mice were stained for VWF (green), CD31 (red) and DAPI (blue). A-C. 
Representative images of distinct brain vessels showing the heterogeneity in VWF 
expression based on their diameter: Small size vessel (6 µm ø) (A); intermediate size vessel 
(29 µm ø) (B) and large vessel (84 µm ø) (C). D. Correlation between the vessel diameter 
and the percentage of VWF area per vessel. (n = 504 vessels from 3 mouse brains). Scale 
bar: 50 µm. 
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Table 2. VWF content in brain vessels according to their diameter 
 VWF content (% endothelial area) 
Vessel Diameter (µm) Mean SD No. of vessels 
0-10 3.6 6.97 289 
10-50 23.3 13.29 106 
>50 29.4 13.84 109 
Note: VWF content differs significantly among each group of vessels; **, P<0.01. Anova. 
 
These results confirm the heterogeneous regulation of VWF expression in the brain 
vasculature. 
 
4.1.3 Molecular mechanisms of melanoma-mediated brain microvascular 
endothelial cell activation 
 
As it was previously shown, melanoma-induced activation of HUVECs is driven by 
two main pathways: indirectly via the generation of thrombin by TF-expressing 
melanoma cells or directly, via secretion of vascular endothelial growth factor A 
(VEGF-A). This interaction results in the exocytosis of WPBs containing VWF and the 
formation of luminal VWF strings (Desch et al. 2012; Kerk et al. 2010).  
In order to assess whether the same molecular mechanisms are involved in the 
crosstalk between melanoma cells and microvascular ECs of the blood-brain barrier 
(BBB), we compared the secretion of VWF in HUVECs and HBMECs upon 
stimulation with, thrombin (0.5 U/ml), VEGF-A165 (2500 pg/ml), the supernatant of Ret 
melanoma cells and HEPES Buffered Ringer’s Solution (HBRS), used as negative 
control.  
The secretion of VWF in the supernatant of ECs was quantified by an enzyme-linked 
immunosorbent assay (ELISA). As expected, the release of VWF by HUVECs was 
significantly increased by thrombin (91.97 ± 30.33 ng/ml) and VEGF-A165 (91.46 ± 
31.62 ng/ml) compared to HBRS-treated cells (42.35 ± 19.38 ng/ml). The addition of 
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the VEGF-A165 antibody Bevacizumab (0.65 mg/mL) blocked the impact of VEGF-
A165 (64.97 ± 21.50 ng/ml). Similarly, Ret supernatant also induced a significant 
release of VWF (97.252 ± 30.877 ng/ml), which was abrogated by addition of 
Bevacizumab (40.90 ± 2.91 ng/ml) (Figure 14 HUVECs). 
Next, HBMEC stimulation was performed under the same conditions. In line with our 
previous findings in section 4.1.1, the resulting concentration of secreted VWF by 
HBMECs was notably low compared to HUVECs (approximately 5-fold decreased). 
Interestingly, in contrast to the strong effect observed in thrombin-induced activation 
of macrovascular HUVECs, thrombin did not induce a notably increase of VWF 
release in HBMECs (11.29 ± 4.915 ng/ml). By contrast, exposure to VEGF-A165 
(21.76 ± 7.25 ng/ml) and Ret Sn (18.02 ± 8.58 ng/ml) significantly increased the 
release of VWF in HBMECs compared to cells treated with HBRS (8.21 ± 6.86 
ng/ml). Bevacizumab reduced the secretion of VWF mediated by VEGF-A165 (13.68 ± 
7.25 ng/ml) and Ret Sn (8.56 ± 2.08 ng/ml) to levels similar to those obtained with 
HBRS (p=0.6645; p>0.999, respectively) (Figure 14 HBMECs). 
 
Figure 14. The molecular mechanisms of EC activation. To evaluate the molecular 
mechanisms involved in the activation of HUVECs and HBMECs, ECs were stimulated for 15 
minutes with HBRS (Control), thrombin (0.5 U/ml), VEGF-A165 (2500 pg/ml) or Ret Sn. 
Additionally, the effect of the VEGF-A165 inhibition with the antibody Bevacizumab (Bevac) 
(0.65 mg/mL) was tested in VEGF-A165 and Ret Sn stimulatory conditions. The concentration 
of VWF in cell supernatants was analyzed by ELISA (n = 9 of 3 independent experiments); 
ns, no significant, *, P < 0.05, **, P < 0.01 (One-way Anova). 
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To investigate the differences in the regulation of HUVECs and HBMECs activation, 
the relative gene expression of EC receptors protease-activated receptor 1 (PAR-1) 
and VEGF receptors 1 and 2 (VEGFR-1,2) were analyzed by qRT-PCR. The results 
of the analysis revealed that the expression of PAR-1 mRNA was relative lower in 
HBMECs compared to HUVECs. By contrast, the expression of VEGFR-2 was 
significantly increased in HBMECs (Figure 15). These findings could explain the 
results obtained in the ELISAs where stimulation of HBMEC with thrombin had no 
effect on VWF secretion, while VEGF-A induced a significant increase of secreted 
VWF outlining the relevance of the VEGF-A/VEGFR-2 signaling axis in the specific 
activation of brain ECs. Additionally, the expression of VWF mRNA was analyzed in 
this assay. The data showed that in HBMECs VWF is expressed in lower degree than 
in HUVECs confirming our immunofluorescence analysis. 
 
Figure 15. Regulation of EC activation. The gene expression of endothelial receptors 
(PAR-1, VEGFR-1 and VEGFR-2), as well as WPBs markers (VWF and P-Selectin) were 
analyzed in HUVECs and HBMECs by q-PCR. The expression of these genes was 
normalized to β -actin. (n = 3 independent experiments); ns, not significant *, P < 0.05, **, 
P < 0.01, (Two-way Anova). Data are presented as mean ± SD. 
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4.1.4 Brain microvascular endothelial cells show a limited capacity to 
form luminal VWF fibers  
 
To further analyze the differences in VWF secretion between macro- and 
microvascular ECs, the formation of luminal VWF fibers was evaluated on HUVECs 
and HBMECs after stimulation. 
The immunofluorescence-based analyses showed that HBRS-treated (control) 
HUVECs, as well as HBMEC, exhibited the characteristic intracellular punctuate VWF 
distribution of quiescent endothelium (Figure 16; HUVECs and HBMECs [control]). 
As expected, stimulation with thrombin (0.5 U/ml), VEGF-A165 (2500 pg/ml) and Ret 
melanoma cell supernatant had a distinct impact on the activation of macorvascular 
HUVECs and HBMECs: in HUVECs thrombin, VEGF-A165 and Ret supernatant 
induced a profound EC activation reflected by the formation of large VWF fibers on 
the apical surface of the EC monolayers (Figure 16; HUVECs). In contrast, the effect 
of the same stimuli on HBMECs was considerably limited: on the one hand, as 
expected thrombin had not effect on the formation of VWF strings in HBMECs. On 
the other, VWF strings were barely visualized upon incubation with VEGF-A and Ret 
supernatant compared to HUVECs (Figure 16 HBMECs, magnifications). 
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Figure 16. Formation of apical VWF strings upon EC activation. HUVECs and 
HBMECs were exposed to HBRS (Control), thrombin (0.5 U/ml), VEGF165 (2500 
pg/ml), Ret Sn for 15 minutes and then fixated with methanol at -20°C. A and B. 
Next, immunofluorescence staining for VWF (green), CD31 (red) and DAPI (blue) 
was performed. Representative images of HUVECs (A) and HBMECs (B) showing 
the differences in VWF string formation. Scale bar: 50 µm. 
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Furthermore, the length of luminal VWF fibers derived from HUVECs or HBMECs 
was measured. The data showed that mean length of HUVEC-derived strings (> 100 
µm) were significantly longer than HBMEC-derived strings (< 50 µm) (Figure 17) 
indicating that the decreased expression of VWF in microvascular ECs limits the 
generation of VWF fibers.  
 
 
Figure 17. Immunofluorescence analysis confirm the formation of VWF 
strings in vitro. The formation of VWF strings was analyzed in HUVECs and 
HBMECs upon stimulation with Ret Sn. Then, ECs were fixated with methanol at -
20°C and stained for VWF (green), CD31 (red) and DAPI (blue). The mean length 
of apical VWF strings was measured in HUVECs and in HBMECs by using 
Fiji/ImageJ (n= 3 independent experiment; > 15 images analyzed per experiment); 
**, P < 0.01 (two tailed, Student's t-test). 
 
Taken together, these results suggest in the first place, strong differences in the 
expression of VWF between the macro- and the microvascular ECs (Figure 12). 
Differences in the VWF abundance were also confirmed in vivo, showing a specific 
regulation of VWF expression in brain vessels depending on their size (Figure 13). 
Additionally, here we revealed the contribution of the VEGF-A/VEGFR-2 axis in tumor 
cell-mediated activation of brain microvascular ECs (Figure 14-17). 
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4.2 Formation of luminal von Willebrand factor fibers is 
associated with brain metastasis 
 
4.2.1 Luminal VWF fibers are detected in human brain metastases 
 
Based on a previous study from our group showing that malignant melanoma 
patients in stage IV exhibit elevated levels of plasmatic VWF (24,239 ± 11,544 
ng/mL) compared to healthy controls (14, 077 ± 4,910 ng/ml) (Bauer, et al. 2015), we 
assessed if a systemic increase of plasmatic VWF concentration was also associated 
with the development of brain metastasis. To confirm this, the concentration of VWF 
was measured in the plasma of 8 patients suffering from brain metastasis of different 
origins. Compared to the plasmatic concentration of VWF in patients with semi-
malignant basal cell carcinoma (BCC) (20,877.50 ± 12,161.63 ng/ml), used as 
control, patients bearing cerebral metastasis showed a significant increase of 
plasmatic VWF (33,518.05 ± 11,095.65 ng/ml) (Figure 18 A).  
Then, we asked whether the increase of plasmatic VWF was due to a systemic loss 
of the activity of a disintegrin and metalloproteinase with a thrombospondin type 1 
motif, member 13 (ADAMTS13). To answer this question we quantified the activity of 
ADAMTS13 in patients’ serum. In control samples, the measured activity of 
ADAMTS13 showed a regular activity (112.2 ± 7.58%). Interestingly, in patients 
suffering from brain metastasis the activity of ADAMTS13 remained unaltered (108 
±7.188%) (Figure 18 B). 
To assess if the increase of plasmatic VWF in patients with brain metastasis is 
reflected by the formation of luminal VWF fibers in cerebral vessels, an 
immunofluorescence analysis was performed on cryosections of brain metastatic 
tissue. CD31 (red) and VWF (green) staining revealed a strong formation of 
intraluminal VWF networks in the vessels of the brain metastatic tissue. (Figure 18 
C). A second immunofluorescence staining for human platelet marker thrombospodin 
(TSP) (red) and VWF (green) confirmed a strong association between luminal VWF 
and platelet aggregates, resulting in the occlusion of cerebral vessels (Figure 18 D). 
Interestingly, this finding indicates an association between brain metastasis and the 
formation of luminal VWF fibers despite the regular activity of ADAMTS13. 
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Figure 18. Brain metastasis is associated with increased levels of plasmatic VWF and 
the formation of luminal VWF fibers. A and B. Concentration of plasmatic VWF (A) as well 
as ADAMTS13 activity (B) was analyzed in blood samples of patients with BCC (Control) and 
brain metastasis. (n = 8 patients/group); ns, not significant *, P < 0.05, (Two-tailed, t-
Student). Data are presented as mean ± SD. C and D. Cryosections of metastatic brain 
tissue were analyzed by immunofluorescence staining for VWF (green) and CD31 (red) (C) 
or thrombospondin (TSP) (red) (D). Nuclei were stained with DAPI (blue). (n = 8 patients). 
Scale bar: 50 µm. 
 
4.2.2 Brain vessels from ret transgenic mice exhibit luminal VWF fibers 
 
To further investigate, if VWF is involved in the hypercoagulability associated with 
brain metastasis, the ret transgenic mouse model (ret mouse) was used. According 
to the literature, after a short period of latency (20 to 70 day of age) ret mice 
spontaneously develop melanocytic tumors (Kimpfler et al. 2009). Then, the animals 
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start to suffer aggressive metastatic processes which initially affect the lymphatic 
nodes and later distant organs as the liver, the lung and the brain (Kato et al. 1998), 
resembling the clinical progression of malignant melanoma in humans. 
To represent malignant melanoma in advanced stage of the disease, 40 ret mice 
were maintained for 100 days (14 weeks) under specific pathogen-free conditions 
(Figure 19 A). Then, brains were harvested and longitudinally cryosectioned to 
evaluate the occurrence of brain metastases. Sections every 100 µm were selected 
to represent the whole brain. In total 32 brains were screened by H&E staining and 
we found that more than 30% of the ret mice developed macroscopic brain 
metastases (Figure 19 B and C). 
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Figure 19. The ret transgenic mouse model A. Schematic overview of our experimental 
settings. Ret mice were maintained under controlled conditions for a maximum of 150 
days with daily monitoring. A. Ret mice show a tumor-free stage of 20 to 70 days before 
the spontaneous development of primary melanocytic tumors with metastases in the lung, 
the liver and the brain. B. Brain metastasis formation was detected by H&E staining 
(dashed line). C. Corresponding quantification of ret mouse brains showing the 
percentage of brains with detectable metastasis (n = 32 mice). Scale bar: 500 µm. 
 
Based on these results, we distinguished 4 different types of brain tissue: Brain tissue 
from healthy wild type mice (Wt). Brain tissue from ret mice without visible 
metastases (Met-free). Peripheral brain tissue from ret mice with macroscopic 
metastases (Peri-Met). And cerebral intra-metastatic tissue (Intra-Met) of ret mice 
(Figure 20). 
 
 
Figure 20. Analysis of ret mouse brain tissue. Brain sections from wild type (Wt) 
(Control) and ret mice were stained for VWF (green), CD31 (red) and DAPI (blue). To 
examine the formation of luminal VWF fibers we distinguished vessels from Wt brains 
(Wt), ret brains without macroscopic metastasis (Met-free) and vessels from ret brains 
with macrometastasis, either from the peripheral tissue (Peri-Met) or from the intra-
metastatic tissue (Intra-Met). Scale bar: 500 µm. 
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Next, the formation of luminal VWF fibers was quantified in healthy (Wt) and ret 
mouse brain vessels by immunofluorescence staining for VWF (green), the 
endothelial cell marker CD31 (red) and DAPI (blue) for nuclei. The corresponding 
quantification showed that in healthy Wt brains, VWF was mostly distributed in the 
vessel wall, indicating the storage of VWF in WPBs, and only some vessels exhibited 
intraluminal VWF fibers (22.28% ± 8.49%). By contrast, the formation of luminal VWF 
fibers was notably enhanced in the vessels of all analyzed groups in ret brain tissues 
(44.11% ± 3.02%) (Figure 21 E). 
 
 
 
 
 
Figure 21. Formation of 
luminal VWF fibers is 
associated with brain 
metastasis. To investigate the 
involvement of VWF in the 
development of brain metastasis 
brain sections from Wt and ret 
mice were stained for VWF 
(green), CD31 (red) and DAPI 
(blue). A-D. We compared the 
formation of luminal VWF fibers 
in vessels from Wt brains (Wt) 
(A), ret brains without 
macroscopic metastasis (Met-
free) (B) and vessels from ret 
brains with metastasis, either 
from the peripheral tissue (Peri-
Met) (C) or from the intra-
metastatic tissue (Intra-Met) (D). 
E. Shown is the percentage of 
cerebral vessels containing 
luminal VWF fibers in each 
group (n = 4-6 animals per 
group); **, P < 0.01 (One-way 
Anova). Data are presented as 
mean ± SD. Scale bars: 50 μm. 
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In line with our previous results showing intraluminal VWF strings in human brain 
metastatic tissue (section 4.2.1), these findings confirmed the presence of luminal 
VWF fibers in ret mouse bearing brain metastasis. Importantly, the formation of VWF 
networks was already significantly increased in metastasis-free brains (41.33% ± 
9.37%). 
 
4.2.3 Endothelial cells are not the main source for VWF fibers in the 
brain vasculature  
 
Quiescent/non-activated endothelium is characterized by the typical punctate VWF 
staining in the vessel wall and virtually no VWF within the vessel lumen. In contrast, 
activation of the endothelium is associated with a clear decrease of VWF abundance 
in the vessel wall, indicative of the exocytosis of WPB-stored VWF. This is usually 
reflected by the formation of ULVWF fibers within the lumen of the activated vessel 
(Bauer, et al. 2015). Interestingly, we observed that the formation of luminal VWF 
strings in ret mouse brain vessels did not correlate with this distribution (Figure 21 B-
D). Therefore, we wondered if the secretion of VWF from activated endothelium is 
involved in the formation of luminal VWF fibers detected in ret brains. 
To address this question we quantified the VWF within the vessel wall and within the 
lumen of brain vessels from healthy (Wt) and ret mice. As controls, vessels from 
healthy skin and primary malignant melanoma tumors were used to represent non-
activated and activated vessels respectively. 
In healthy skin vessels, VWF was strongly located in the vessel wall with little 
presence of VWF within the lumen (Figure 22 A-I and C). This distribution is 
characteristic of non-activated endothelium, with VWF stored in endothelial WPBs. 
By contrast, the amount of VWF in the endothelium of primary tumor vessels was 
importantly reduced, correlating with a strong generation of intraluminal VWF fibers 
(Figure 22 A-II and C) indicative of activated endothelium with subsequent secretion 
of VWF into the vessel lumen. In the brain, vessels from healthy Wt mouse exhibited 
a distribution of VWF similar to non-activated vessels in healthy skin, with VWF 
stored in the vessel wall and almost no luminal VWF fibers. (Figure 22 B-I and C). 
Moreover, and in line with the observations from the primary tumor (Figure 22 A-II), 
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vessels of ret Intra-Met brain tissue exhibited a pronounced formation of luminal VWF 
fibers associated with a significant decrease of endothelial VWF (Figure 22 B-IV and 
C). Luminal VWF networks were also found in ret Peri-Met brains vessels. However, 
these vessels also showed a strong VWF signal in the wall, indicative of non-
activated endothelium (Figure 22 B-II and C). Interestingly, the same distribution 
was detected in the vessels from ret Met-Free brain tissue (Figure 22 B-III and C). 
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Figure 22. Luminal VWF fiber formation is not associated with a decrease of 
endothelial VWF in the brain vasculature. A. Representative examples of non-activated 
vessels (I Healthy skin vessel) and activated vessel (II Primary tumor vessel). B. The 
distribution of VWF was analyzed in brain vessels from Wt brains (I), ret Met-Free (II), ret 
Peri-Met (III) and ret Intra-Met (IV). C. The percentage of the area occupied by VWF in the 
endothelium (Endothelial VWF) and within the lumen (Luminal VWF) was quantified by 
using Fiji/ImageJ (n = 24-117 vessels per group); ns, not significant *, P< 0.05, **, 
P<0.001, (Two way Anova). Data are presented as mean ± SD. Scale bars: 50 μm. 
 
These results indicate that endothelial VWF could not be the major source for the 
observed VWF network formation in brain vessels and suggests the contribution of 
plasmatic VWF multimers or platelet-derived VWF. 
 
4.2.4 Platelet-derived VWF contributes to the formation of luminal VWF 
fibers in brain vessels 
 
Next to ECs, platelets store VWF in α-granules (Garam et al. 2018). Platelet-derived 
VWF represents an important source of VWF providing about 20% of plasmatic VWF 
within the blood (Peyvandi, Garagiola, and Baronciani 2011b). Given the 
heterogeneous distribution of VWF in the brain vasculature and the restricted 
secretion of VWF by brain vessels, we asked whether platelet activation and 
secretion of α-granule might be responsible for the luminal VWF fibers in ret 
transgenic mouse brains. 
To answer this question, we first evaluated the activation of platelets in ret brains with 
or without metastasis. Because activated thrombocytes bind to fibrinogen via the 
active GpIIb/IIIa (or αIIbβ3) integrin complex (Nieswandt, Varga-Szabo, and Elvers 
2009), an in situ fribinogen binding assay was performed. To this end, brain sections 
were incubated with Alexa Fluor® 488-conjugated fibrinogen and later were stained 
for the platelet marker CD42 (or GpIbα) (red) and DAPI (blue) for nuclei. 
In Figure 23, representative images of brain vessels show the differences on of 
platelet-fibrinogen interaction in healthy Wt versus ret brains. Platelet-fibrinogen 
interaction was measured by the t-Mander’s coefficient of colocalization (Fiji/Image 
J). Our analyses revealed that in brain vessels from healthy Wt mice intraluminal 
platelet-fibrinogen interaction was a minor event. In contrast, in ret mice the 
colocalization of intraluminal platelets and fibrinogen was significantly enhanced in ret 
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Met-Free brains (2.95-fold), ret Peri-Met (2.79-fold) and ret Intra-Met (2.96-fold). 
(Figure 23 B). This result suggests that platelet activation may be enhanced during 
brain metastasis. It is important to note that in line with our previous result showing 
an increased formation of luminal VWF fibers in ret Met-Free brains (section 4.2.3), 
enhanced fibrinogen-CD42 colocalization was also detected in metastasis-free 
brains.  
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Figure 23. Platelet-fibrinogen interaction is enhanced in brain metastasis. To 
identify activated platelets in situ, a fibrinogen binding assay was performed. Tissue 
sections were incubated with Alexa Fluor®488-conjugated fibrinogen (white) and stained 
for CD42 (red) and DAPI (blue). A. Representative images show the interaction between 
fibrinogen and platelets in wild type (Wt) and ret transgenic (ret) mouse brain vessels. B. 
CD42-Fibrinogen interaction was quantified by the Mander's colocalization coefficient 
(Fiji/Image J). Values in each group were normalized to the results obtained in Wt brains. 
(n= 4-6 mice per group); **, P < 0.01, (One-way Anova). Data are presented as mean ± 
SD. Scale bar: 50 μm. 
 
In addition, an immunofluorescence analysis for VWF (green) and CD42 (red) was 
performed in brain cryosections of Wt and ret brains, to determine whether the 
secretion of VWF stored in platelet α-granules was associated with the formation of 
luminal fibers. Platelets identified in the lumen of healthy Wt brain vessels exhibited a 
discoid morphology with a intracellular punctuate distribution of VWF indicative of 
resting platelets storing VWF in α-granules (Figure 24 A). By contrast, in ret brain 
vessels an enhanced number of platelets showed pseudopodial projections, which 
are considered a feature of activated platelets (Modic et al. 2014). Additionally, 
platelets with pseudopodia were found in a strong association with VWF fibers 
suggesting the secretion of VWF stored in α-granules. In addition, EC-derived VWF 
remained in the vessel wall (Figure 24 B and C) excepting in the vessel walls of 
intratumoral vessels were endothelial staining for VWF was not clearly detected 
(Figure 24 D). In conclusion, pronounced fibrinogen binding in combination with the 
strong association of platelets with luminal VWF fibers, indicate that platelet 
activation related to the brain metastatic cascade. 
In line with this, platelet activation in ret brain correlated with an increase in 
thrombocyte aggregation. To quantify the formation of platelet aggregates, the mean 
area of CD42 positive individual platelets was measured by ImageJ/Fiji (NIH). With 
this value, the number of platelets involved in each luminal CD42-positive aggregate 
was stimated. Thereby, we could distinguish between single platelets (1-2 platelets) 
and platelet aggregates (>2 platelets). The corresponding quantification showed that 
the mean number of single platelets in each vessel did not differ significantly among 
the groups. Nevertheless, the number of platelet aggregates per vessel significantly 
increased in the vessels of ret Met-Free (9.41 ± 3.01 aggregates/vessel), in ret Peri-
Met (11.13 ± 2.66 aggregates/vessel) and in ret Intra-Met (8.16 ±1.09 
aggregates/vessel) brains compared to Wt brain vessels (4.75 ± 1.41 
4. Results 
67 
 
aggregates/vessel) (Figure 24 E). These results confirm that platelet-secreted VWF 
contributes to the formation of platelet-rich thrombi.  
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Figure 24. VWF-Platelet aggregates are increased in brain metastasis. Brain sections 
were stained for VWF (green), for CD42 (red), and DAPI (blue). A-D. Images show the 
differences between endothelial-derived VWF and platelet-derived VWF secretion 
between healthy (Wt) (A) and ret brains (B-D). E. Luminal platelet area was measured to 
analyze the formation of platelet-rich thrombi in brain vessels (n=4-6 brains per group); ns, 
not significant *, P < 0.05, **, P < 0.01 (One-way Anova). 
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4.3 Platelet-derived von Willebrand factor and thrombus 
formation 
 
4.3.1 Platelet-secreted VWF contributes to platelet aggregation 
 
To determine if the contribution of endothelial-derived and platelet-derived VWF 
differs in the occlusion of cerebral microvessels, we investigated the mechanisms 
underlying the formation of platelet-rich microthrobi in vitro.  
First, we studied the impact of different agonists on the activation of ECs and 
platelets. For this purpose, macrovascular HUVECs and brain murine microvascular 
bEND3 were exposed to thrombin (0.5 U/ml), histamine (10 µM) or collagen type I 
(50 µg/ml). The effect of thrombin-mediated VWF release was detected only in 
HUVECs but not in bEND3. Moreover, histamine induced a significant increase of 
VWF secretion in both HUVECs and bEND3. By contrast, collagen type I had no 
effect neither on HUVECs nor on bEND3 (Figure 25 A and B). In parallel, the 
aggregation of platelets was examined after incubation of isolated thrombocytes with 
the same agonists. Light transmission aggregometry (LTA) assays revealed a strong 
aggregation of platelets mediated by thrombin and collagen type I but not by 
histamine (Figure 25 C). In conclusion, our experiments revealed that histamine is an 
important agonist of EC activation but has no effect on platelet aggregation. In 
contrast, collagen type I mediates platelet aggregation without any effect on VWF 
secretion by ECs. 
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Figure 25. Different agonists are required for EC andr platelet activation. A and B. 
HUVECs (A) and bEND3 (B) were stimulated with HBRS (Control), collagen I (50 µg/ml), 
histamine (10 µM) and thrombin (0.5 U/ml) and the supernatant was analyzed for VWF 
release by ELISA (n = 3 independent experiments); ns, no significant, **, P < 0.01 
(Student's t-test). C. The impact of these agonists was evaluated on platelet aggregation 
by LTA. (n = 4 independent experiments); **, P < 0.01 (F-test). 
 
The different steps in the formation of a platelet-rich thrombus were studied by 
implementation of an in vitro microfluidic system that mimics the conditions within the 
vasculature. HUVECs and HBMECs were seeded in separated microfluidic slides 
and perfused with washed human platelets in absence of plasmatic factors. Based on 
the previous results EC activation was induced by histamine addition (100 µM). The 
formation of luminal VWF strings was visualized by the formation of the so-called 
“platelets on a string” structures, indicative of the initial platelet adhesion. At this 
point, platelet coverage was measured and the results showed that in HUVEC layers 
(1650 ± 501.8 µm2) thrombocyte adhesion was notably greater than in HBMECs (683 
± 269.60 µm2) (Figure 26 A and C [platelet adhesion]). In a second step, the addition 
of collagen type I (50 µg/ml) evoked the activation of platelets leading to their 
aggregation and the subsequent formation of thrombocyte plugs (Figure 26 B). The 
corresponding quantification showed that platelet coverage increased significantly 
both in HUVECs (7923 ± 1800.1 µm2) and in HBMECs (2238 ± 600.9 µm2) (Figure 
26 C [platelet aggregation]). Interestingly, despite the differences in the initial 
adhesion of platelets between HUVECs and HBMEC, the relative increase of platelet 
coverage after collagen I addition was similar on HUVEC and HBMEC monolayers, 
showing approximately 4-fold increase of platelet deposition. This indicates that 
whereas theinitial adhesion of thrombocytes is mediated by endothelial derived VWF 
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strings, platelet aggregation is induced mainly by the specific activation of 
thrombocytes. Additionally, these data suggests that the restricted secretion of VWF 
in brain ECs may protect against an excessive deposition of thrombocytes in the 
brain vasculature preventing the potential occlusion of brain microvessels. 
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Figure 26. Platelet binding and aggregation in distinct vascular beds. The effect of 
the low VWF abundance in brain microvascular ECs was evaluated on the formation of 
platelet-rich thrombi under flow conditions. A and B. HUVEC and HBMEC monolayers 
were perfused with human labeled-platelets. EC activation was induced by histamine (1 
U/ml) mediating platelet adhesion (A). In a second step, platelet activation and 
subsequent aggregation was induced by collagen type I (50 μg/ml) (B). C. Platelet 
coverage was quantified at the initial adhesion of platelets and after aggregation in 12 
independent fields per experiment (n = 3 experiments); *, P < 0.05, **, P < 0.01 (two 
tailed, Student's t-test).Scale bar: 50 µm. 
 
 
To proof that platelet-derived VWF plays a critical role in thrombus formation within 
the brain vasculature, isolated platelets from Wt or VWF-/- mice were perfused over 
murine bEND3 monolayers. The initial adhesion of platelets was mediated by 
histamine addition (100 µM). No significant differences were found in the formation of 
thrombocyte strings between Wt (132.72± 38.19 µm2) and VWF-/- platelets (57.43 ± 
51.09 µm2) (Figure 27 A and C). Next, the formation of platelet plugs was evaluated 
after addition of collagen type I (50 µg/ml). Wt platelets exhibited a regular response 
to collagen, forming platelet aggregates and increasing the platelet coverage (311.55 
± 121.32 µm2). However, VWF-/- platelets showed a defective aggregation upon 
collagen addition, resulting in a non-significant increase of thrombocyte surface 
coverage (74.59 ± 42.51 µm2) (Figure 27 A and C). These findingsindicate the 
importance of α-granule-secreted VWF in the aggregation of platelets. To confirm 
this, aggregation of purified Wt and VWF-/- platelets was evaluated by LTA in 
absence of plasmatic factors (including plasmatic VWF). In line with our previous 
results, LTA showed that the formation of platelet aggregates was significantly 
reduced in platelets lacking VWF (59%) in comparison with Wt platelets (72%), 
highlighting the important contribution of platelet-derived VWF in the formation of 
platelet aggregates. (Figure 27 D). These results provide a new insight into the 
mechanism of thrombus formation and confirmed that platelet-derived VWF plays a 
critical role in the aggregation of activated platelets in the vasculature of the brain. 
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Figure 27. Platelet-derived VWF mediates the formation of platelet aggregates. The 
contribution of platelet-derived VWF on thrombus formation was analyzed by using 
microfluidic devices. The murine bEND3 cells were perfused with platelets from Wt or 
VWF knockout (VWF KO) mice. A and B. The murine bEND3 cells were perfused with 
platelets from Wt or VWF knockout (VWF KO) mice. bEND3 activation was induced by 
histamine (1 U/ml) mediating platelet adhesion (A). In a second step, platelet activation 
and subsequent aggregation was induced by collagen type I (50 μg/ml) (B). C. Size of 
platelet coverage at the initial adhesion of platelets and after aggregation was quantified in 
12 independent fields per experiment (n = 4-6 experiments); *, P < 0.05, **, P < 0.01 (two 
tailed, Student's t-test). D. The capacity of Wt and VWF KO platelets to form aggregates 
was determined by light transmission aggregometry (LTA) after activation with collagen 
type I (50 μg/ml) (n = 4 independent experiments); *, P < 0.05. (F-test). Data are 
presented as mean ± SD. Scale bar: 50 μm. 
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4.3.2 Impact of distinct anticoagulants on platelet activation 
 
Besides its involvement in thrombocyte aggregation, the secretion of platelet α-
granules is also involved in the modulation of vascular permeability (Leblanc and 
Peyruchaud 2016). One of the major regulators of vascular integrity and development 
is VEGF, which includes VEGF-A, VEGF-B and placental growth factor (Greenberg 
and Jin 2013). Importantly, platelet α-granules are an prominent source of VEGF-A 
(Cloutier et al. 2012). 
To ensure whether the activation of platelets results in the secretion of α-granules, 
the supernatant of activated thrombocytes was analyzed for VEGF-A secretion. Our 
analyses demonstrated that in the absence of plasmatic factors, collagen type I (50 
µg/ml) and thrombin (0.5 U/ml) induce the activation and the subsequent aggregation 
of platelets correlated with a significant increase of secreted VEGF-A in platelet 
supernatant compared to non-activated platelet (Figure 28 A and B).Because it is 
known that anticoagulant heparins interfere in the communication between tumor 
cells and thrombocytes (Ponert et al. 2018), the impact on platelet activation and 
VEGF-A secretion of the low molecular weight heparin (LMWH) Tinzaparin and the 
pentasaccharide Fondaparinux was evaluated. Our analyses revealed that the 
aggregation of platelets was abrogated by Tinzaparin (100 U/ml) and this correlated 
with a strong reduction of platelet-derived VEGF-A secretion (12.54 ± 6.42 pg/ml). 
(Figure 28 A and B). In contrast, preincubation with Fondaparinux did not show any 
effect on platelet aggregation and only induced a partial reduction of VEGF-A 
secretion in platelet releasates (33.56 ± 19.38 pg/ml).  
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Figure 28. Tinzaparin blocks platelet activation and platelet-derived VEGF-A. The 
impact of distinct anticoagulants on platelet aggregation was examined by LTA. A. Platelets 
were preincubated for 30 minutes with 100 U/ml of Tinzaparin (Tinza) or 50 µg/ml of 
Fondaparinux (Fonda) and then, collagen type I (50 µg/ml) and thrombin (0.5 U/ml) was used 
as platelet agonist (n = 4 independent experiments); *, P < 0.05 (F-test). B. Supernatants of 
platelets were analyzed by ELISA for VEGF-A (n = 3 independent experiments); ns, non-
significant, *, P < 0.05 (One-way Anova). 
 
4.3.3 Tinzaparin reduces platelet-mediated endothelial permeability and 
tumor cell transmigration 
 
Platelet-secreted VEGF-A is known to promote vascular permeability and tumor cell 
extravasation (Meikle et al. 2016). Therefore, we tested the impact of platelet-derived 
VEGF-A on the transendothelial permeability of brain EC monolayers and tumor cell 
transmigration.  
First, we examined the effect of platelet activation on the transendothelial electrical 
resistance (TEER) of HBMEC monolayers. HBMECs seeded on an electric cell-
substrate impedance sensing (ECIS) array (Applied BioPhysics Inc., NY, USA) were 
coincubated with platelet releasates for 24 hours and changes in the TEER were 
measured every 48 seconds (Figure 29 A). The results revealed that collagen type I 
(50µg/ml)-activated platelet releasates induced a significant decrease of HBMECs 
TEER (-426.6 ± 101.1 Ωcm2) compared to resting platelet releasates (-246.6 ± 107.8 
Ωcm2) (Figure 29 B). In contrast, preincubation of platelets with Tinzaparin (100 U/ml) 
before activation significantly reduced the effect of platelet releasates on TEER (-
317.4 ± 45.25 Ωcm2). Similarly, Bevacizumab (0.65 mg/mL), an antibody against 
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VEGF-A, strongly inhibited the impact of platelet-supernatant on TEER (-247 ± 95.85 
Ωcm2) highlighting the role of platelet-secreted VEGF-A in the disruption of brain 
endothelial barrier.  
The impact of platelet supernatant on Ret melanoma cell transmigration was 
evaluated in a trans-well system seeded with HBMECs (Figure 29 C). Incubation 
with the supernatant of collagen type I-activated platelets increased the number of 
transmigrated Ret cells through the endothelial barrier (68.58 ± 12.39 Ret cells/field) 
compared to Ret cells incubated with the supernatant of resting platelets (38.22 ± 
16.89 Ret cells/field). By contrast, the number of transmigrated tumor cells was 
significantly reduced by the preincubation of platelets with Tinzaparin (37.23 ± 8.21 
Ret cells/field). This effect was also detected after incubation of platelets with 
Bevacizumab (43.28 ± 12.90 Ret cells/field) (Figure 29 D). 
In summary, these data suggest that the activation of arrested platelets may generate 
a local increase of VEGF-A in the microvasculature of the brain, promoting local 
permeability changes and tumor cell extravasation.   
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Figure 29.Tinzaparin attenuates platelet-mediated brain EC permeability and tumor cell 
transmigration. A. HBMEC monolayers were incubated with the supernatants of resting 
platelets (Rest Plt Sn) or with the supernatant of collagen type I (50 µg/ml)-activated platelets 
(Act Plt Sn), with or without a preincubation with Tinzaparin (100 U/ml; Act Plt Sn [Tinza]) or 
Bevacizumab (0.65 mg/ml; Act Plt Sn [Bevac]). Transendothelial electrical resistance (TEER) 
was used to evaluate endothelial integrity (n = 6 of 3 independent experiment per group). B. 
Bars show the absolute decrease of TEER in each group after incubation with platelet 
releasates. Data are presented as mean ± SD. *, P< 0.05, **, P<0.01 (Student's t-test).C. 
Schematic diagram of the tumor cell transmigration assay: Ret melanoma cells were co-
incubated for 8 hours with the supernatant of resting platelets (rest Plt Sn), activated platelets 
(act Plt Sn) and activated platelets preincubated with Tinzaparin (100 U/ml) or Bevacizumab 
(0.65 mg/mL) (act Plt Sn +Tinza/Bevac). Then, upper chambers were removed and 
transmigrated tumor cells counted after 24 hours. D. shown is the corresponding 
quantification of transmigrated tumor cells (n = 6 of 3 independent experiments); *, P < 0.05, 
**, P < 0.01 (One-way Anova). Data are presented as mean ± SD. 
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4.4 Effect of anticoagulation with Tinzaparin on brain 
metastasis formation 
 
Our in vitro results demonstrated the inhibitory effect of Tinzaparin on platelet 
activation and subsequent VEGF-A secretion. Besides, our results showed 
Tinzaparin reduced the effect of platelet-derived VEGF-A on transendothelial 
permeability and tumor cell transmigration through a brain EC monolayer. These 
findings suggest potential benefits of Tinzaparin in the prevention of cerebral 
metastasis. 
 
4.4.1 Tinzaparin reduces platelet activation in vivo 
 
To examine the impact of Tinzaparin on platelet activation in vivo, ret mice were 
subcutaneous injected with Tinzaparin for 100 days (0.6 U/kg daily) (n = 20 mice). As 
control, a group of mice received a daily injection of a saline solution (NaCl) (n = 20).  
First, we investigated of the impact of Tinzaparin on platelet activation in ret mouse 
brains. To this end, an in situ fibrinogen binding assay was performed as described 
before (section 4.2.4). Briefly, brain cryosections of ret mice treated with Tinzaparin 
or with NaCl were incubated with fluorescently labeled fibrinogen and later stained 
with CD42 antibody for platelets. If platelet activation occurs, active GpIIIb/IIa is 
exposed on the surface of activated platelets and is able to bind fibrinogen. Images 
of ret brain vessels in Figure 30 A and B show how the colocalization between 
fibrinogen (white) and platelets (red) is enhanced in a ret mouse treated with NaCl 
compared to a ret mouse treated with Tinzaparin. This interaction was quantified as it 
is described before (section 4.2.4) and the results were normalized to the values 
obtained from the control group (NaCl). The analysis showed that in all the groups 
analyzed the interaction between fibrinogen and platelets was reduced by 50% in 
Tinzaparin-treated mice  compared to the control group treated with NaCl (Figure 30 
B).  
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Figure 30. Tinzaparin attenuates platelet activation in vivo. To identify activated platelets 
in situ, a fibrinogen binding assay was performed. Tissue sections were incubated with Alexa 
Fluor®488-conjugated Fibrinogen (white) and stained for CD42 (red) and DAPI (blue).A-B. 
The activation of platelets was analyzed in brains of ret mice treated with NaCl (control 
group) (A) or Tinzaparin (Tinza) (0.6 IU/g) (B) for 100 days. C. CD42-Fibrinogen t-Manders 
coefficient of colocalization (Fiji/Image J) was calculated in each vessel and normalized to 
the results obtained in the control group. (n= 3-6 mice per group); *, P < 0.05, (two-way 
Anova). Scale bar: 50 µm. 
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4.4.2 Inhibition of platelet activation by Tinzaparin reduces the formation 
of luminal VWF fibers 
 
Whether Tinzaparin reduces the activation of platelets in vivo, this phenomenon 
should be reflected by a decrease of α-granules secretion and, thus, a reduction of 
intraluminal VWF fibers. To prove this, an immunofluorescence staining for VWF 
(green), the endothelial cell marker CD31 (red) and DAPI (blue) for nuclei was 
performed on brain cryosections of ret mice treated with Tinzaparin or with NaCl 
(control). 
Immunofluorescence analyses revealed that the generation of intraluminal VWF 
fibers was strongly reduced in ret mice treated with Tinzaparin compared to the 
control group (Figure 31 A and B). The corresponding quantification confirmed that 
the formation of circulating VWF strings was approximately reduced by 50% in ret 
mice treated with Tinzaparin compared to NaCl-treated control mice (Figure 31 C). 
This is in line with the previous result showing similar a decrease of platelet-
fibrinogen interaction. 
 
 
4. Results 
81 
 
 
Figure 31. Platelet-derived VWF secretion is inhibited by Tinzaparin in vivo. To investigate the 
impact on the formation of luminal VWF fibers, brain sections from ret mice treated with NaCl 
(control group) or Tinzaparin (0.6 U/kg daily) were stained for VWF (green), CD31 (red) and DAPI 
(blue). A and B. Representative images showing the differences in the formation of luminal VWF 
fibers in brain vessels of a NaCl-treated ret mouse (A) and Tinzaparin-treated ret mouse(B). C. The 
number of vessels containing VWF fibers within the lumen of cerebral vessels was quantified in 
both groups and normalized to the results seen in the control group (n = 5-6 animals per group); 
*, P < 0.01 (Two-way Anova). Data are presented as mean ± SD. Scale bar: 50 μm. 
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4.4.3 Tinzaparin treatment reduces platelet aggregation in the the 
cerebral vasculature of ret mice  
 
Based on our previous in vitro assays showing the relevance of platelet-derived VWF 
in platelet aggregation, we analyzed if the inhibition of platelet-derived VWF fiber 
formation by Tinzaparin interfered in the aggregation of thrombocytes in vivo. 
Therefore, an immunofluorescence staining for VWF (green) and CD42 (red) was 
performed in brain cryosections of ret mice treated with Tinzaparin or with NaCl 
(control).  
The staining revealed notable differences in the morphology of circulating platelets 
ndicating differences in the activation state of these cells. In the control group treated 
with NaCl, platelets exhibiting pseudopodia protrusions were localized in close 
contact with luminal VWF fibers, mediating the formation of thrombocyte aggregates 
(Figure 32 A; magnifications). By contrast, Tinzaparin-treated mice showed 
circulating single platelets with the characteristic morphology of inactive state, 
characterized by a discoid-like shape and cytoplasmic storage of VWF (Figure 32 B; 
magnifications). These findings together with the observations described before 
(section 4.4.1 and 4.4.2) suggest a strong inhibitory effect of Tinzaparin on platelet 
activation in vivo. Indeed, compared to NaCl-treated ret mice, the number of 
intravascular thrombocyte aggregates was significantly reduced by 50% in 
Tinzaparin-treated mice in all the groups analyzed (Figure 32 C).  
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Figure 32. Tinzaparin reduces platelet aggregation in vivo. The impact of Tinzaparin 
on platelet aggregation was examined by immunofluorescence staining for VWF (green), 
CD42 (red), and DAPI (blue) on brain sections from ret mice treated with NaCl (control) or 
Tinzaparin (0.6 U/kg daily). A and B. Images represent the differences in platelet 
aggregation between ret mice treated with NaCl (A) or Tinzaparin (B). C. Luminal platelet 
area was measured to analyze the formation of platelet aggregates. The corresponding 
quantification shows the mean number of aggregates per vessels normalized to the 
results in the control group (n=4-6 brains per group); ns, not significant *, P < 0.05, **, P < 
0.01 (two-way Anova). Scale bar: 50 µm. 
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4.4.4 Anticoagulation with Tinzaparin reduces the metastatic load in the 
brain 
 
In close collaboration with the group of Prof. Dr. Winkler in the DKFZ in Heidelberg, 
the direct impact of Tinzaparin on metastasis formation was evaluated in amouse 
model for brain metastasis formation based on the  intracardial (i.c.) injection of 
melanoma cells (section 3.2.3).  
The i.c. injection of A2058 human melanoma cells was performed in 8-12 weeks old 
male NMRI-nu/nu mice. Treatment with the anticoagulant LMWH Tinzaparin (0.6 
U/kg) was started two days prior IC injection and continued daily until day 10 after IC 
injection. Mice were maintained under specific pathogen-free conditions until the 
ultimate endpoint on day 31 after the IC injection (Figure 33 A). Then, brains were 
sectioned coronally (10 µm thick sections) and H&E staining was performed to 
determine the size of the metastatic lesions (Figure 33 B). As shown in Figure 33 C, 
the area of the metastatic lesions was significantly reduced in Tinzaparin-treated 
mice in comparison to non-treated control mice. This result highlights the therapeutic 
effect of Tinzaparin attenuating the metastatic load in the brain. 
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Figure 33. Anticoagulation with Tinzaparin reduces platelet activation and attenuates 
brain metastasis formation. A. To assess the effect of Tinzaparin on the formation of brain 
metastasis, an intracardiac injection (i.c.) of melanoma cells was implemented: Tinzaparin 
(0.6 U/kg daily) was administrated 2 days prior to heart injection of melanoma cells (A2058) 
and continued with daily application until day 10 after the injection. B. H&E staining was 
performed to quantify the tumor load at day 31. Magnifications show melanoma brain 
metastases and the outline used for area calculations. C. mean metastasis area and tumor 
area per brain tissue was quantified in Tinzaparin-treated (Tinza) and non-treated (control) 
mice (n= at least 3 animals per group); *, P < 0.05 (Student's t-test). Data are presented as 
mean ± SD. Scale bars: 1mm (overview); 200μm (magnification). 
 
In summary, our in vivo findings suggest that the formation of platelet-derived luminal 
VWF strings play an important contribution in platelet aggregation and thrombus 
generation in the context of brain metastasis. Importantly, blocking platelet activation 
and α-granule-VWF secretion by the LMWH Tinzaparin reduces the thrombus 
formation and decreases the metastatic load in the brain. 
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5. Discussion 
 
This study intends to understand the role of von Willebrand factor (VWF) in tumor 
progression and brain metastasis-associated thrombosis. In summary, our results 
reveal: (I) Brain microvascular endothelial cells (ECs) show a low expression of VWF 
and a restricted formation of luminal VWF fibers. (II) Immunofluorescence analyses 
indicate that platelet activation and subsequent secretion of α-granule-stored VWF 
accounts for the luminal VWF fibers observed in the brains of ret transgenic mice, 
which spontaneously develop melanoma with brain metastasis. (III) Platelet-derived 
VWF mediates the formation of thrombocyte aggregates generating a local increase 
of VEGF-A which mediates the disruption of the brain endothelium and promotes the 
transmigration of tumor cells. (IV) The anticoagulant low molecular weight heparin 
(LMWH) Tinzaparin inhibits platelet activation and subsequent aggregation, reducing 
the local increase of VEGF-A. (V) Anticoagulation with Tinzaparin reduces the 
formation of intravascular VWF-platelet aggregates in the brains of ret transgenic 
mice. (VI) Treatment with the anticoagulant LMWH Tinzaparin attenuates the 
metastatic load in the brain upon intracardial injection of melanoma cells. 
 
5.1.  Von Willebrand factor in cancer and thrombosis 
 
As previously mentioned, thromboembolic events, principally venous 
thromboembolism (VTE) are frequent complications in malignant melanoma patients 
(Sparsa, et al. 2011). Particularly, the incidence of VTE increases in patients 
suffering from melanoma brain metastasis (Alvarado et al. 2012). Given its main role 
in blood hemostasis and coagulation, it has been suggested that VWF may play a 
relevant contribution to cancer-associated thrombogenicity (Pépin et al. 2016). 
Indeed, multiple types of cancer characterized by an high risk of VTE, such as breast 
cancer, pancreatic cancer, gastrointestinal cancers, ovarian carcinoma or bladder 
carcinoma are also associated with elevated levels of plasmatic VWF, suggesting the 
contribution of VWF in the thrombotic complications (Franchini et al. 2013; Röhsig et 
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al. 2001). Besides, it has been suggested that the prothrombotic activity observed in 
cancer patients may increase the risk of metastasis (O’Sullivan et al. 2018). 
Consistent with this, elevated levels of plasmatic VWF have been correlated with the 
presence of metastases in different types of cancers such as gastric cancer, 
metastatic colorectal carcinoma or metastatic larynx cancer (Paczuski et al. 1999;. 
Wang et al. 2005; Yang et al. 2018). These data highlight the potential involvement of 
VWF in tumor progression.  
Despite the increasing number of clinical evidence showing the contribution of VWF 
in cancer progression, the underlying mechanisms of how VWF is involved in 
metastasis are still not clear. To address this question, different experimental animal 
models have been implemented to elucidate the role of VWF in tumor progression. 
On the one hand, it has been described that VWF regulates tumor vascularization, 
since VWF controls ECs proliferation by downregulation of angiopoietin 2 (Ang-2) 
(Yuan et al. 2016). Indeed, isolated ECs from patients with von Willebrand disease 
type 3 (entailed a complete lack of VWF expression) show an enhanced expression 
and release of angiopoietin 2 (Ang-2) (Starke et al. 2013). Moreover, VWF also 
promotes VEGFR-2-αvβ3 integrin interaction, which reduces the affinity of VEGF-R2 
for its ligands (Randi and Laffan 2017a). Consequently, the genetic depletion of VWF 
in mice leads to an enhanced tumor vascularization (Goertz, et al. 2016; Randi and 
Laffan 2017b). Taken together, these findings suggest that VWF might play an anti-
tumor role decreasing tumor angiogenesis. In line with this, in 2006 Terraube and 
colleagues showed that VWF-deficient animals exhibited an increased pulmonary 
metastasis compared to wild type (Wt) mice (Terraube et al. 2006) a process related 
to increased vascular permeability (Wolf et al. 2012). Consistent with this, a recent 
study from our group showed a similar increased in the number of lung metastatic 
foci in VWF-deficient mice (Goertz, et al. 2016). Interestingly, in the same study a 
disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 
(ADAMTS13)-deficient mouse, characterized by prolonged lifetime of luminal VWF 
fibers showed an enhanced lung metastasis compared to VWF-deficient mice. 
Similarly, in other studies the specific depletion of VWF with antibodies reduced the 
metastasis in different experimental mouse models (Karpatkin et al. 1988; O’Sullivan 
et al. 2018) supporting the prometastatic role of VWF in tumor progression.  
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These contrasting data could be explained by the fact that VWF plays a critical role in 
the formation of Weibel-Palade bodies (WPBs) (Peyvandi, Garagiola, and Baronciani 
2011). Indeed, the absence of VWF is associated with the complete lack of WPBs (de 
Wit and van Mourik 2001). Consequently, VWF deficient mice suffer a dysregulation 
of WPB constituents, such as P-selectin, Ang-2 and interleukin 8 which regulate the 
integrity of the vasculature (Starke et al., 2011). This alters the physiology of the 
endothelium and increases its permeability (Melgar-Lesmes et al. 2009) and might 
contribute to the enhanced metastasis observed in VWF-deficient mice (Suidan et al. 
2013). Therefore, the absence of VWF should not be considered the main 
responsible for the enhanced metastasis observed in VWF-deficient mice. Indeed, in 
vitro studies have shown that melanoma cells induce a profound secretion of 
endothelial WPBs containing VWF, which results in the formation of luminal VWF 
strings (Desch et al. 2012; Kerk et al. 2010). Moreover, it was shown that those 
strings mediate the adhesion of thrombocytes (Huck et al. 2014a). In vivo studies 
have also revealed that the tumor microenvironment induces the activation of ECs, 
reflected by the formation of intraluminal VWF networks and the formation of platelet 
aggregates and subsequent vessel occlusion (Bauer, et al. 2015). Importantly, the 
activation of ECs is also promoted in distal organs, where the formation of luminal 
VWF networks is correlated with enhanced metastasis suggesting the contribution of 
VWF in tumor cell extravasation (Goertz, et al. 2016). Indeed, it has been 
demonstrated that the formation of VWF-thrombocyte aggregates increases the 
vascular permeability and facilitates extravasation of leukocytes (Petri et al. 2010). 
These findings support a model wherein VWF might promote tumor cell extravasation 
and thrombus formation through the activation of ECs and the generation of luminal 
VWF fibers. Luminal VWF networks mediate platelet aggregation and the binding of 
tumor cells to the vessel wall. The formation of a thrombus increases the permeability 
of the vessel wall and favors the extravasation of metastatic cells (Figure 34). 
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Figure 34. Contribution of VWF fibers to thrombosis and cancer metastasis. Tumor 
cells promote the activation of ECs at distant organs. The subsequent secretion and 
activation of VWF leads to the formation of luminal VWF fibers, which in turn mediates the 
recruitment of platelets and the formation of thrombocyte aggregates. Platelet-VWF 
aggregates promote the arrest of circulating tumor cells. The secretion of platelet derived 
factors increases vascular permeability and facilitates tumor cell extravasation. 
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5.2 Role of von Willebrand factor in pathologies of the 
central nervous system 
 
Despite patients with brain tumor exhibit one of the highest incidence of VTE (Ay et 
al. 2010; Pabinger, Thaler, and Ay 2013), the contribution of VWF in intracranial 
hypercoagulation and brain metastasis is still unclear.  
In 2008 Noubade and colleagues described the impact of VWF on Pertussis toxin 
(PTX)-mediated encephalomyelitis. They observed that the disruption of the blood-
brain barrier (BBB) upon PTX insults was more severe in VWF-deficient mice than in 
Wt mice, suggesting a protective role of VWF in the maintenance of BBB integrity 
(Noubade et al. 2008). However, many studies report the opposite effect of VWF in 
diverse cerebral pathologies. For instance, it was described that the absence of VWF 
decreases the flexibility and the permeability of the BBB in experimental mouse 
models of hypoxia/reoxygenation and pilocarpine-induced status epilepticus (Suidan 
et al. 2013b). In line with this, the absence of VWF in transgenic mice was shown to 
decrease the infarct volume and reduce the concentration of inflammatory mediators 
after ischemic insults (Zhu et al. 2016a). Consequently, the restoration of VWF 
expression, by hydrodynamic infusion of a plasmid encoding for VWF recovers the 
susceptibility for strokes in VWF-deficient mice, increasing the infarct volume to 
comparable levels observed in Wt mice (Kleinschnitz et al. 2009). Similar results 
were obtained in a study where the degradation of luminal VWF was enhanced by 
the infusion of recombinant ADAMTS13, decreasing the volume of the infarct in an 
experimental stroke model (Canault et al. 2009). Strikingly, Fujioka and coworkers 
reported the prothrombotic potential of VWF in the brain vasculature showing the 
increased susceptibility of ADAMTS13-deficient mice to suffer thrombotic episodes in 
a mouse model of transient cerebral ischemia (Fujioka et al. 2010).  
Given that most of the recent data sustain a model where VWF comprises the 
integrity of the BBB and contributes in the occlusion of brain microvessels, it is 
tempting to think that VWF might play a prometastatic role in the brain, mediating the 
formation of thrombi within the brain vasculature which increases the vascular 
permeability and facilitating the arrest of circulating tumor cells (CTCs). 
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5.3 Distinct expression of von Willebrand factor in 
different vascular beds 
 
The expression of VWF is considered a major biomarker for ECs (Goncharov et al. 
2017). However, ECs represent a heterogeneous population, whose biological 
properties differ not only between distinct tissues but also within the different types of 
vessels in the same organ (Cines et al. 1998). Therefore, is tempting to speculate 
that heterogeneity of the distinct vascular beds may modulate the expression and 
functionality of VWF. 
Only a few studies have outlined the differences in the expression and distribution of 
VWF between the distinct vascular beds. In 1998, Yamamoto and colleagues 
performed a systemic analysis of VWF mRNA and antigen expression along the 
different vasculatures of the mouse: they found significant differences in VWF levels 
between ECs from different tissues and also between venous and arterial ECs 
(Yamamoto et al. 1998). This finding was supported by another study showing that 
VWF distribution is heterogeneous in the murine vasculature. Interestingly they 
described the correlation between the individual size of the vessels and the 
expression of VWF (Müller et al. 2002b). This particular distribution of endothelial 
VWF has been also confirmed in distinct human tissues showing a heterogeneous 
distribution of VWF within individual vessels and even in different sections of the 
same organ (Pusztaszeri, Seelentag, and Bosman 2006).  
In line with this, our results showed notables differences in the abundance and 
distribution of VWF between macrovascular human umbilical vein ECs (HUVECs) 
and human brain microvascular ECs (HBMECs). We observed that the number of 
HBMECs storing intracellular VWF was significantly lower than in HUVECs (Figure 
12 A-C). Additionally, the number of Weibel-Palade bodies (WPBs) storing VWF per 
cell was also significantly reduced in HBMECs compared to HUVECs (Figure 12 D). 
In vivo analyses of VWF expression in the brain vasculature of wild type (Wt) mouse 
brains also confirmed a segregated distribution of VWF in brain vessels: VWF was 
expressed predominantly in vessels with large diameters (≥ 50 µm), while in smaller 
capillaries (≤ 10 µm) the presence of VWF was only marginal (Figure 13 and Table 
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2). This pattern of VWF distribution suggests the local specialization of brain ECs to 
perform distinct functions within the brain vasculature. Consistent with this, it has 
been described that the low expression of VWF in small capillaries is associated with 
sites of regulated transport processes, while bigger vessels with abundant VWF are 
related to inflammation and cell extravasation (Macdonald, Murugesan, and Pachter 
2010). 
Based on these findings we wondered if the particular expression of VWF in the brain 
vasculature might affect the tumor-induced procoagulant activity of brain 
microvascular ECs. 
 
5.3.1 Distinct molecular mechanisms in brain endothelial cell activation. 
 
The interaction between tumor cells and the endothelium is an essential prerequisite 
in the pathogenesis of tumor metastasis. Earlier studies from our group demonstrated 
that tumor cell-mediated thrombin generation and the secretion of VEGF-A induce 
the activation of ECs and the exocytosis of WPB containing VWF (Desch et al. 2012; 
Kerk et al. 2010). Own results show that thrombin-, as well as VEGF-A- and Ret 
supernatant induce an acute activation of macrovascular human umbilical vein ECs 
(HUVECs), reflected by increased levels of secreted VWF (Figure 14; HUVECs) and 
the formation of luminal VWF strings on the luminal surface of HUVEC monolayers 
(Figure 16; HUVECs). In strong agreement with other authors reporting the 
procoagulant role of thrombin and VEGF-A in cancer spreading (Borensztajn et al. 
2009; Mahecha and Wang 2017), here it is shown the contribution of these two 
molecules in tumor-associated hypercoagulability by turning the endothelium into a 
proinflammatory and procoagulatory surface.  
However, the impact of thrombin and VEGF-A on the activation of brain 
microvascular ECs is notably distinct in comparison to macrovascular ECs: on the 
one hand, thrombin fails to activate HBMECs (Figure 14) and, thus, luminal VWF are 
barely present after incubation with thrombin (Figure 16). This fact might be 
explained by the limited expression of thrombin receptor protease-activated receptor-
1 (PAR-1) in HBMEC compared to HUVECs (Figure 15). Interestingly, it is known 
that the central nervous system (CNS) exhibits a special procoagulant environment 
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which is defined by an enhanced expression of tissue factor (TF), prothrombin 
(Dihanich et al. 1991; Mackman et al. 1993) and a low expression of tissue factor 
pathway inhibitor (TFPI) (Bajaj et al. 1999), together protect the brain against 
bleedings (Mark 2013). However, an excessive procoagulant activity may enhance 
the risk of suffering from diffuse microvascular thrombotic complications upon 
pathophysiological conditions. Therefore, we purpose that the restricted expression 
of PAR-1 might act as a protective mechanism at the microvascular level against an 
enhanced activation of brain microvascular ECs. Conversely, we also observed that 
VEGF-A induces a significant increase of secreted VWF in brain microvascular ECs, 
suggesting the importance of VEGF-A/VEGFR-2 axis in the activation of brain 
microvascular ECs (Figure 14; HBMECs). This observation is supported by our 
mRNA analyses showing an upregulation of VEGF-R2 in HBMECs compared to 
HUVECs (Figure 15). This finding indicates the relevance of VEGF-A, rather than 
thrombin in the crosstalk between tumor cells and the brain vasculature. 
Taken together these results reflect the distinct molecular mechanisms regulating the 
activation of distinct vascular beds. In addition, here is also shown that the low 
amount of VWF expressed in microvascular brain ECs combined with the restricted 
secretion of VWF limits the generation of luminal VWF strings in vitro, suggesting that 
brain vasculature regulates the VWF expression to reduce the risk of thrombotic 
occlusion of brain vessels and support the regular blood flow.  
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5.4 The formation of luminal von Willebrand factor fibers 
is associated with melanoma brain metastases 
 
In the in vivo situation the micromilieu within a melanoma tumor promotes the 
activation of ECs, the consequent formation of luminal ultra-large VWF fibers 
(ULVWF) mediate the aggregation of thrombocytes leading to the thrombotic 
occlusion of tumor microvessels (Bauer, et al. 2015). The formation of ULVWF fibers 
is also detected in organs distal to the primary tumors mediating the formation of 
thrombi, which suggests the role of VWF in the thrombosis related to cancer (Goertz, 
et al. 2016). Nevertheless, the cerebro-specific regulation of VWF described before 
raises the question of whether VWF also participates in the hypercoagulability 
associated with melanoma cerebral metastasis.  
Our own results reveal that patients suffering from brain metastasis exhibit elevated 
levels of plasmatic VWF (Figure 18 A) and they are associated with the formation of 
intraluminal VWF networks mediating the thrombotic occlusion of cerebral vessels 
(Figure 18 C and D). In strong agreement, immunofluorescence analyses of brains 
from ret transgenic mice with cerebral metastasis confirm the formation of luminal 
VWF fibers. Importantly, intravascular VWF networks are also detected in ret brains 
without visible metastasis, suggesting that the generation of VWF fibers may indicate 
an early stage of cerebral metastasis (Figure 21). This is in line with the growing 
body of evidence pointing out the link between hypercoagulability and tumor 
progression (Caine et al. 2002; Falanga, Marchetti, and Vignoli 2013). Indeed, this 
finding might provide a possible mechanism of how hemostatic factors, such as VWF 
and thrombocytes serve as a bridge between the pathological hypercoagulation 
associated with cancer diseases and metastasis. Indeed, it has been reported that 
VWF fiber-mediated thrombocyte accumulation contributes to the creation of a 
microenvironment promoting the survival and proliferation of tumor cells (Gay and 
Felding-Habermann 2011). 
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5.4.1 Platelet-derived von Willebrand factor contributes to the formation 
of luminal fibers in the brain vasculature 
 
Considering our previous results showing a heterogeneous expression of VWF in the 
brain vasculature, the restricted activation and the limited secretion of VWF in brain 
ECs (section 4.1), one might expect that pathophysiological conditions in the brain 
should not be associated with a strong formation of intraluminal VWF networks and 
platelet recruitment. By contrast, as described above, a strong formation of 
intraluminal VWF networks was significantly enhanced in the context of brain 
metastasis (section 4.2).  
Therefore, we sought to determine the source of those VWF strings. Our data show 
that similarly to primary tumor vessels, intratumoral vessels from metastatic tissue in 
ret brains exhibit luminal VWF networks associated with a decrease of VWF stored in 
the vessel wall. However, the formation of intraluminal VWF fibers in the peripheral 
tissue surrounding the metastases, as well as in vessels from ret brains without 
visible tumors does not correlate with a decrease of endothelial VWF (Figure 22). 
These data seem to indicate that VWF fibers within the cerebral vessels are not 
derived from the brain ECs, but rather reflect plasmatic VWF multimers or platelet-
secreted VWF strings. Indeed, ex vivo perfusion assays with blood from patients 
suffering type I von Willebrand disease (VWD) with platelets expressing VWF 
demonstrated the importance of platelet-derived VWF in thrombus formation 
(Fressinaud et al. 1994). In line with this, Kanaji and coworkers demonstrated that in 
the absence of endothelial VWF thrombocyte-derived VWF partially restores blood 
hemostasis in a chimeric mouse expressing VWF only in platelets (Kanaji et al. 
2012). 
Platelets store VWF in α-granules (Wagner et al. 1991). The secretion of α-granules 
is induced upon platelet activation (Lenting et al. 2018), a process regulated by the 
interaction between platelet surface receptors and their agonists (Yun et al. 2016). 
The heterodimeric transmembrane GpIIb/IIIa (αIIbβ3) integrin is the most abundant 
integrin receptor in the platelet surface and mediates the interaction between 
fibrin(ogen) and platelets (Fuchs, Bhandari, and Wagner 2011). Under resting 
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conditions, GpIIb/IIIa exhibits a low affinity for its binding partner, however, platelet 
activation induces a conformational change in GpIIb/IIIa that increases its affinity for 
fibrin(ogen) (Nieswandt, Varga-szabo, and Elvers 2009). In particular, it has been 
observed that the interaction between platelets and fibrin(ogen) is enhanced in the 
context of metastasis and it has been shown that platelet-fibrin(ogen) aggregates 
protect tumor cells from immune surveillance (Palumbo et al. 2005). Our analyses 
demonstrate a strong interaction between platelets and fibrinogen in ret brains in 
comparison to healthy wild type mouse brains (Figure 23). Interestingly, the 
association between platelets and fibrinogen is already increased in metastasis-free 
ret brains, suggesting that the activation of platelets is enhanced in the premetastatic 
context. Interestingly, the activation of GpIIb/IIIa in platelets has been also related to 
the exocytosis of α-granules and the formation of platelet-derived VWF strings 
(Lonsdorf et al. 2012). To confirm that platelet activation is promoted in brain 
metastasis, immunofluorescence analyses were performed. The results show how 
activated platelets, identified by the characteristic emission of pseudopods are 
identified in close contact with intraluminal VWF fibers, meanwhile, the endothelial-
derived VWF remained stored in the vessel wall (Figure 24 A-D). This is in strong 
agreement with the data reported by Verhenne and colleagues describing that 
whereas platelet-derived VWF is not essential for the normal hemostasis, it plays a 
relevant role in thrombo-inflammatory complications in the brain (Verhenne et al. 
2015).  
In addition, it has been reported that specific N-linked glycosylation in thrombocyte-
derived VWF confers resistance against the enzymatic degradation by ADAMTS13 
(McGrath et al. 2010). This could explain why we observe VWF networks in the brain 
vessels of patients with brain metastases despite the regular activity of ADAMTS13 
found in the plasma of the same patients (section 4.2.1). This is consistent with 
previous clinical studies showing unaffected ADAMTS13 activity in patients bearing 
brain metastasis (Böhm et al. 2003). Furthermore, platelet-derived VWF is 
characterized by a strong affinity for activated platelet-GpIIb/IIIa, while endothelial 
VWF binds to resting platelet-GPIb more efficiently (Williams et al. 1994). This 
indicates a distinct contribution of endothelial-derived and platelet-derived VWF in the 
initial stages of the platelet adhesion and thrombosis, respectively. Consistent with 
this, we observed that the aggregation of thrombocytes is strongly promoted in ret 
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brains, despite the endothelial VWF remains stored in the vessel wall (Figure 24 E). 
These results outline the contribution of platelet-secreted VWF, rather than EC-
derived VWF in the prothrombotic activity associated with brain metastasis. 
Ex vivo perfusion assays with human thrombocytes support these findings. Our 
assessments demonstrate that the initial adhesion of platelets to the vasculature and 
the formation of platelet aggregates are two separated processes, subordinated to 
distinct regulation: Firstly, EC activation and the formation of luminal VWF strings 
mediates the recruitment of platelets. Secondly, thrombocyte activation and VWF 
secretion promote the aggregation of further activated platelets and the formation of 
a thrombus (Figure 26 A and B). As expected, due to the greater expression of VWF 
in macrovascular ECs, the adhesion of thrombocytes is increased in comparison to 
microvascular brain ECs. This in line with other studies showing that the abundance 
of endothelial-VWF in cultured ECs affects the size and adhesive capacity of VWF 
strings (Ferraro et al. 2016). In spite of this, our analysis shows that the augment of 
thrombocyte coverage upon platelet aggregation is proportional in both cell types 
(Figure 26 C), suggesting the exclusive contribution of platelet-secreted VWF in the 
aggregation of platelets. To confirm this, we tested the capacity of platelets lacking 
VWF (VWF-/-) to form microthrombi at the microvasculature of the brain. Our 
perfusion experiments show that that VWF-/- platelets generate significant smaller 
platelet plugs than Wt platelets (Figure 27 A-C). Indeed, comparable results have 
been observed in a study reporting that the aggregation of platelets is inhibited when 
platelets lack α-granules (platelet decoys) (Papa et al. 2019). Similarly, our 
aggregation assays reveal that the lack of VWF in platelets significantly slows down 
the aggregation of platelets compared to Wt platelets (Figure 27 D). These results 
indicate the relevant contribution of VWF stored in α-granules in thrombocyte 
bundling. 
Based on these results we postulated that activated thrombocytes promote the 
formation of microthrombi which compromise the integrity of the BBB and facilitate 
the cerebral: The inflammatory conditions associated to malignant diseases promotes 
the activation of brain ECs and the formation of luminal VWF fibers which mediate 
the recruitment of thrombocytes (1). The activation of thrombocytes and the 
subsequent secretion of α-granule-stored VWF (2) mediates the aggregation of 
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platelets (3). Thrombocyte aggregates generate a local increase of permeability 
factors (4) which increase the permeability of the brain vasculature and favors tumor 
cell extravasation (5) (Figure 35). 
 
Figure 35. Contribution of activated thrombocytes in cerebral metastastasis: 
Procoagulant environment associated with malignant diseases promotes the initial 
adhesion of thrombocytes on brain vessels (1-2). Activation of platelets and the 
subsequent secretion of VWF induce the aggregation of further platelets (3). The 
formation of a platelet-rich microthrombus leads to a local increase of permeability factors 
(4) which disrupt the vascular integrity and promote tumor cell extravasation (5).  
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5.5 Systemic anticoagulation attenuates the metastatic 
load in the brain 
 
Our results highlight the impact of VEGF-A on the activation of primary brain 
microvascular ECs (section 4.1.3). Interestingly, thrombocyte α-granules are an 
important source of bioactive VEGF-A which is known to modulate the endothelial 
integrity (Salgado et al. 2001; Schumacher et al. 2013).  
Indeed, many studies have reported the contribution of VEGF-A in such diverse 
cerebral pathologies as ischemic stroke or Alzheimer (Greenberg and Jin 2013; 
Harris et al. 2017). In the context of cerebral metastasis, it has been reported that the 
expression of VEGF-A by breast cancer cells is associated with an enhanced risk of 
suffering from metastasis in the brain (Lee et al. 2004; Yang, Wang, and Ma 2018). 
Own findings demonstrate that VEGF-A secreted by activated platelets comprises the 
integrity of brain EC monolayer and promotes the extravasation of tumor cells 
(Figure 29). This is in line with a previous study showing that platelet activation and 
α-granule secretion promote vascular disruption and tumor cell transmigration 
(Schumacher et al. 2013). Others authors have confirmed in vivo the contribution of 
VEGF-A in cerebral malignancy by showing that antiangiogenic therapy with VEGFR-
2 inhibitors resulted in less metastasis and tumor growth retardation due to an 
impaired development of tumor vasculature (Bohn et al. 2017; Boult et al. 2017; 
Farzaneh Behelgardi et al. 2018). The angiogenic process regulated by VEGF-A 
entails a series of morphological and intracellular changes which transiently disrupt 
the integrity of the endothelial barrier (Song et al. 2014) this situation facilitates the 
cell extravasation and promotes the metastatic invasion of the brain (Suzuki, Nagai, 
and Umemura 2016; Zhang et al. 2000).  
Therefore, a VEGF-A-targeted therapy sounds like a promising approach to reduce 
the contribution of activated platelets in brain metastasis. In line with this, it was 
shown that the depletion of VEGF-A with specific antibodies reduces the growth of 
tumor vasculature and induces the dormancy of intracranial metastasis (Kienast et al. 
2010). However, an anti-VEGF-A treatment implies side effects as bleedings or 
thrombotic events due to the physiological role of VEGF in vessel maturation (Nalluri 
et al. 2008b; Y. Yang et al. 2013). Therefore, is important to find alternative 
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approaches to mitigate the activity of VEGF-A without entailing any risk for bleedings 
or thrombotic complications for the patients. 
 
5.5.1 The low molecular weight heparin Tinzaparin prevents tumor cell 
transmigration by blocking platelet-secreted VEGF-A  
 
Low molecular weight heparins (LMWHs) are a class of anticoagulant medication, 
which are widely implemented in the treatment of thrombotic complications: blood 
clots and VTEs (including deep vein thrombosis and pulmonary embolism) and in the 
treatment of myocardial infarctions (V. V Kakkar et al.2000; Solari and Varacallo 
2019). Importantly, many studies have shown the benefits of LMWHs preventing 
thrombotic complications with minimal impact on bleedings (Quinlan, McQuillan, and 
Eikelboom 2004).  
LMWHS are generated by the depolymerization of full-length unfractionated heparins 
(UFHs) chains, which are a large variety of biomolecules with size ranges from 3 to 
30 kDa (Johnson and Mulloy 1976). The anticoagulant functions of heparins are 
known for at least four decades and are based on the affinity of their pentasaccharide 
molecular structure for Antithrombin III (AT III), an important inhibitor of FXa and 
thrombin (Danielsson et al. 1986; Rosenberg and Damus 1973). Indeed, the 
interaction between AT III and the pentasaccharide structure of heparins enhances 
the activity of AT III 1000-fold (Olson et al. 1992). The benefits of using LMWHs over 
UFH are based on its reduced cost-effective compared to UFH (Hatam et al. 2017), 
their greater bioavailability by subcutaneous injection (Weitz 1997) and their longer 
half-life (Bradbrook et al. 1987). Moreover, it has been shown that LMWHs exhibit 
additional functions due to the variability of the structures obtained after UFH 
fractionation (Rutering et al. 2016). Some of these additional properties include the 
induction of TFPI release from endothelial cells (Ma et al. 2007) or the inhibition of 
angiogenesis (Norrby 2006; Villares, Zigler, and Bar-Eli 2011).  
In the context of cancer disease, LMWHs are often used to ameliorate the 
hypercoagulable state of the patients (Kakkar 2009). Some clinical studies have 
shown the benefits of anticoagulant therapy with LMWHs improving the prognosis 
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and the survival of cancer patients (Kuderer, Ortel, and Francis 2009). Nowadays 
many anti-cancer properties have been attributed to LMWHs, such as the inhibition of 
angiogenesis associated to tumor progression (Norrby 2006) or the impairment of the 
interaction between tumor cells and P-selectin reducing significantly tumor 
colonization of new tissue (Läubli, Varki, and Borsig 2016). In line with this, our group 
has identified an additional antimetastatic property of the LMWH Tinzaparin blocking 
tumor-secreted VEGF-A (Bauer 2015).  
Based on this, we used Tinzaparin to understand the underlying mechanism of 
platelet activation and the impact of platelet-secreted VEGF-A on this process, the 
thrombocyte aggregation in the absence of coagulation factors was tested in the 
presence of Tinzaparin or Fondaparinux. Fondaparinux is a synthetic 
pentasaccharide that inhibits factor Xa-mediated thrombin generation, but unlike 
Tinzaparin exhibits low affinity for VEGF-A (Bauer, et al. 2015; Buyue, Misenheimer, 
and Sheehan 2012). The results show that Fondaparinux did not show any effect on 
platelet aggregation (Figure 28 A; Fonda). As expected, the absence of coagulation 
factors in our in vitro settings explains the lack of effect of Fondaparinux. In contrast, 
platelet aggregation was completely abrogated by Tinzaprin (Figure 28 A; Tinza). 
Since the plasmatic coagulation factors are absence, it is reasonable to think that 
platelets mediate their activation in an autocrine fashion through the secretion of α-
granule constituents. It is known that platelets expressed VEGFR-2 on their surface 
(Yang, Wang, and Ma 2018) and our results show that thrombocyte activation leads 
to the secretion of VEGF-A (Figure 28 B). Therefore, we speculate that secretion of 
VEGF-A by the initial activation of thrombocytes fosters the activation of further 
platelets. Nevertheless, in the presence of Tinzaparin, platelet-derived VEGF-A is 
rapidly blocked due to the strong affinity exhibited by these two molecules (Bauer, et 
al. 2015) and, thus, further platelet activation is inhibited. In line with this, a recent 
publication showed the inhibitory effect of Tinzaparin on platelet activation by 
coagulation factors-independent pathways (Gockel et al. 2018).  
As has been already mentioned, platelet-derived releasates mediate the disruption of 
a brain EC barrier which increases the number of transmigrated tumor cells (section 
4.3.3). The contribution of platelets mediating the vascular permeability is well 
established (Leblanc and Peyruchaud 2016a; Li 2016). Platelets store a big plethora 
5. Discussion 
 
102 
 
 
of permeability mediators, such as matrix metalloproteinases (MMPs), adenosine 
triphosphate (ATP) and diverse growth factors like VEGF or interleukins (Gay and 
Felding-Habermann 2011). Here, using the anti-VEGF-A antibody Bevacizumab, we 
identify platelet-secreted VEGF-A as the main mediator of brain EC disruption and 
tumor cell extravasation. In the same extent, Tinzaparin reduces the permeability and 
tumor cell transmigration mediated by platelet releasates, evidencing the inhibitory 
effect of Tinzaparin on platelet-secreted VEGF-A (Figure 29). 
These results highlight the relevance of platelet-derived VEGF-A mediating tumor cell 
transmigration through the BBB and suggest the benefits of a systemic 
anticoagulation therapy with Tinzaprin to prevent platelet contribution in cerebral 
metastasis. 
 
5.5.2 Anticoagulant therapy with Tinzaparin reduces brain metastasis-
associated thrombosis and attenuates brain metastasis  
 
Anticoagulation with LMWHs is one of the most common first line treatment for the 
prevention of thrombotic complications in cancer patients (Kearon et al. 2016). During 
the last years, a great number of clinical studies have examined whether besides 
their anticoagulant function, LMWHs also exhibit anti-metastatic properties. However 
the results obtained are conflictive.  
For instance, in a meta-analysis including more than 700 studies the impact of 
LMWHs on the overall survival of patients was examined and the results concluded 
that LMWHs do not influence the outcome of patients (Sanford et al. 2014). However, 
in this study the data were not treated consistently, cancer patients with different 
tumor types, in different stages and treated with different LMWHs were included in 
the meta-analysis. Thus, one cannot exclude the different properties of distinct 
LMWHs and their effect on distinct types of cancer (Läubli, Varki, and Borsig 2016). 
And this is in line with the distinct anti-tumorigenic effects obtained by the 
implementation of different clinical approved LMWHs. For example, Dalteparin 
(CLOT trial) and Tinzaarin (CATCH trial) demonstrated their benefits versus oral 
anticoagulants reducing the thrombotic events in cancer patients( Lee 2003; Lee et 
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al. 2015). However, regarding their anti-tumorigenic impact, on the hand, Dalteparin 
demonstrated only a moderate survival benefit in certain subpopulations of cancer 
patients (FAMOUS trial) (Kakkar et al. 2004). On the other, Tinzaparin shows 
contradictoy effects. The first clinical trial which revealed a significant survival benefit 
in tumor patients implemented Logiparin, which was later known as Tinzaparin (Hull 
et al. 1992). However, recently it was shown that Tinzaparin has no impact on the 
survival of patients with pulmonary metastasis (Meyer et al. 2018).  
Therefore, these controversial results suggest that further investigation of the distinct 
properties of different LMWHs must be performed to elucidate the specific 
therapeutic limitations of each LMWH. Consistent with this, here it has been tested 
the distinct properties of different anticoagulants. As described, Fondaparinux has no 
direct effect on platelet activation compared to Tinzaparin. This is in line with recent 
findings from our group showing that Fondaparinux has a reduced impact on the 
inhibition of tumor angiogenesis compared Tinzaparin (Goertz, et al. 2016). Another 
example is the distinct effect of different LMWHs on VEGF-A activity. Our group 
reported that Tinzaparin exhibits a strong affinity for VEGF-A, blocking its activity 
(Bauer, et al. 2015). By contrast, it is known that the LMWH Dalteparin increases the 
activity of VEGF-A enhancing tumor angiogenesis in vivo (Norrby and Nordenhem 
2010).  
Furthermore, the treatment of thromboembolic complications in patients bearing brain 
metastases is especially challenging because of the high risk of suffering intracranial 
hemorrhages (Donato et al. 2015). During the last years, LMWHs have demonstrated 
their therapeutic potential improving the outcome of the patients without increasing 
the risk of intracranial bleedings (Alvarado et al. 2012; Lin, Green, and Shah 2018). 
However, as it was mention before the identification of effective anticoagulant 
treatments is crucial for a successful therapy. Thus, in this study we have examined 
the impact of Tinzaparin on the hypercoagulability associated with brain metastasis. 
Our in vivo assays show that Tinzaparin therapy reduces platelet activation in the 
brain of ret transgenic mice (Figure 30). Consequently, platelet inhibition leads to a 
lower secretion of α-granule-derived VWF from activated platelets (Figure 31) and 
therefore the aggregation of platelets and the subsequent occlusion of brain vessels 
is reduced compared with ret mice treated with a saline solution (Figure 32). These 
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findings provide more evidence that demonstrate the pivotal role of platelet-derived 
VWF in the formation of microthrombi associated with brain metastasis and support 
the benefits of Tinzaprin inhibiting platelet-aggregation in vivo. To prove the impact of 
Tinzaparin treatment on the formation of brain metastases, mice daily treated with 
Tinzaparin or with a saline solution were intracardially injected with melanoma cells to 
induce the formation of intracerebral metastases. The formation of brain metastases 
was quantified at the end of the experiment revealing that the metastatic load in the 
brain was significantly reduced in Tinzaparin-treated mice (Figure 33). These results 
suggest that the activation of platelets and the subsequent formation of intracranial 
microthrombi promote the invasion and proliferation of metastatic cells in the brain, 
however, the implementation of an anticoagulant treatment with the LMWH 
Tinzaparin ameliorates the formation of platelet aggregates and attenuates the 
metastasis in the brain. 
 
.
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6. Conclusions 
 
Based on previous studies showing the influence of platelets on transendothelial 
permeability (Fang et al. 2014; Schumacher et al. 2013), our results indicate that 
platelets contribute to the opening of the blood-brain barrier and promote tumor cell 
extravasation principally by the secretion of VEGF-A. Previous studies suggest that 
inhibition of VEGF-A with a specific antibody prevents angiogenic growth and 
intracranial metastasis (Kienast et al. 2010). Therefore, VEGF-A-targeted therapy 
sounds like a promising approach to interfere with the prometastatic activity of 
platelets, but entails the risk of compromising the hemostasis and promote thrombotic 
complications (Nalluri et al. 2008a; Y. Yang et al. 2013). An alternative approach to 
treat brain metastases could be to target the coagulation on the one hand and the 
secretion of platelet-derived VEGF-A on the other hand, with only one drug. For 
instance, with LMWH  that attenuate the activation of platelets and thus the secretion 
of angiogenic proteins, such as VEGF-A (Battinelli et al. 2014). Here, we show that 
the LMWH Tinzaparin reduces platelet-mediated transmigration of melanoma cells, 
tumor-associated thrombotic vessel occlusion and the formation of intracranial 
macrometastases.  
In summary, our data provide a new insight into the role of platelet-secreted VWF 
and increase our knowledge about the mechanisms underlying thrombotic 
complications associated with cerebral metastasis. Thus, cancer patients with high 
risk for suffering thrombotic complications and brain metastases may benefit from an 
anticoagulant treatment with LMWHs (Figure 36). 
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Figure 36. Tinzaparin-mediated inhibition of platelet activation attenuates brain 
metastasis: Thrombocyte activation and the subsequent secretion of VWF promotes the 
formation of platelet aggregates in the brain. Tinzaparin inhibits platelet activation and 
reduces the formation of platelet aggregates protecting the integrity of the BBB. 
 .  
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